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ABSTRACT
CELLULAR MECHANISM OF ARGLABIN- 
DIMETHYLAMINOHYDROCHLORIDE CYTOTOXICITY
Xiaofei Qin
Old Dominion University and Eastern Virginia Medical School, 2006 
Director: Dr. Christopher J. Osgood
Cancer is the second leading killer in the United States. Anticancer drug 
development is always based on the understanding of molecular and cellular mechanisms 
of carcinogenesis, as well as comprehensive knowledge of potential anticancer drugs. 
Arglabin-dimethylaminohydrochloride (arglabin-DMA) represents one of the new classes 
of anti-cancer agents that have shown promise in suppressing the growth of various 
tumor cells. However, the cellular mechanism of arglabin-DMA cytotoxic effects on 
tumor cells is still unclear. The current study was to determine the famesyltransferase 
(FTase) inhibitory activity of arglabin-DMA and to investigate the effects of arglabin- 
DMA on three proteins: Ras, Rho and cyclin kinase inhibitor p21 /WAF1 /CIP1.
In vitro FTase assays were used to study the effect of arglabin-DMA on FTase 
activity. The FTase assay using expressed FTase showed that the 50% inhibition 
concentration of arglabin-DMA was 2.9 mM. The FTase assay using lysates of Ras/3T3 
cells that had been incubated with arglabin-DMA showed that the highest FTase 
inhibition was 59% as compared to the no treatment control, and this inhibition plateaued 
when the arglabin-DMA concentration was 100 nM or higher. These results suggested 
that arglabin-DMA was transformed in cells and that the transformed arglabin-DMA 
inhibited FTase activity in Ras/3T3 cells. However, this inhibition was limited by the 
substrate availability in cells that may transform arglabin-DMA to an FTase inhibitor.
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The study of the effects of arglabin-DMA on Ras protein, Rho protein, and cyclin 
kinase inhibitor p21 /WAF1/CIP1 was performed using Ras/3T3 cells incubated with 
arglabin-DMA or FTI-277 (positive control) for 24 or 72 hours. Western blots and 
densitometry showed a decreased ratio of processed to unprocessed H-Ras protein in cell 
lysates incubated with 100 pM of arglabin-DMA. Western blotting of active H-Ras 
protein from GTPase pull-down assays showed significant reduction of active H-Ras 
after incubation with 50 pM of arglabin-DMA for 24 hours, or 1 pM of arglabin-DMA 
for 72 hours. Only unprocessed RhoA was detected by Western blot after incubation with 
10 pM (or higher) arglabin-DMA or FTI-277. Western blots showed a trend of increased 
p21/WAFl/CIPl production after 72 hours of incubation with arglabin-DMA and this 
increase was not found in the FTI-277 control.
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INTRODUCTION
RAS PROTEINS AND ASSOCIATED SIGNAL TRANSDUCTION PATHWAY
Ras genes encode a family of GTP-binding proteins (p21 Ras) known to play major 
roles in controlling cell growth and differentiation (55). Three genes encode four 
isoforms of Ras protein: H-Ras, N-Ras, Ki-Ras4A and Ki-Ras4B. Ki-Ras4A and Ki- 
Ras4B are splice variants of the same gene (61, 67). H-Ras mutations are primarily found 
in carcinomas of the bladder, kidney, and thyroid. N-Ras mutations are primarily found in 
myeloid and lymphoid disorders, liver carcinoma, and melanoma. Ki-Ras mutations 
predominate in colon and pancreatic carcinomas (61).
Cycling between the active GTP-bound form and inactive GDP-bound form, p21 Ras 
protein acts as a regulatory switch in cell signaling. In normal cell signaling, inactivation 
of p21 Ras protein occurs through hydrolysis of bound GTP to GDP by the protein’s 
intrinsic GTPase activity coupled with strong stimulation by GTPase-activating protein 
(GAP) (47, 55). Both normal and oncogenic forms of Ras protein share similar GTP/GDP 
binding properties, however, they differ in their ability to hydrolyze bound GTP. The 
weak GTPase activity of normal Ras protein is reduced approximately tenfold further in 
the oncogenic Ras protein. Moreover, the oncogenic forms of Ras protein are insensitive 
to GAP which functions to accelerate the slow intrinsic rate of GTP hydrolysis by normal 
Ras protein. The most frequently detected alterations in oncogenes in both animal tumor 
model systems and in human cancers are mutations in the ras family of oncogenes, which 
includes single point mutations at codons 12, 13, 61, or 117, or by alteration of mRNA
The journal model is Molecular and Cellular Biology.
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splicing. Specific mutations in the ras gene impair GTPase activity and response to GAP 
of p21 Ras protein, rendering it constituitively active and resulting in uncontrolled cell 
growth and morphologic transformation of normal cells.
The Ras system is a ubiquitous signal transduction pathway that is part of the signal 
transduction system for multiple tyrosine kinase receptors such as those for the epidermal 
growth factor (EGF), platelet-derived growth factor (PDGF), and fibroblast growth factor 
(FGF) (Fig. 1) (27, 55). When a ligand binds its receptor, receptor dimerization occurs, 
triggering an autophosphorylation event and an interaction with “adaptor” proteins called 
Grb2 and Sos. Grb2 complexes with the tyrosine kinase receptor and the Sos protein via 
the Src protein homology domains called SH2 and SH3, respectively. Grb2 SH3 domains 
bind to proline-rich sequences present in Sos, allowing recruitment of Sos to the plasma 
membrane where Ras is bound. Sos activates Ras, and this activation results in release of 
GDP and binding of GTP. The activated Ras complexes with Raf protein, and this 
binding can induce a conformational change in Raf that activates its kinase activity. 
Activated Raf then phosphorylates a second kinase called MEK (mitogen-activated 
protein kinase kinase or MAPKK). MEK phosphorylates and thereby activates a third 
kinase, MAP kinase (MAPK), which has among its substrates various transcription 
factors such as Jun/Fos (AP-1) that regulate gene expression (27, 55, 63). This “kinase 
cascade” is a crucial signaling pathway regulating growth and differentiation in many cell 
types (Fig. 1).
In order for Ras protein to transduce its normal or oncogenic signal, it must be 
anchored to cell membranes, which include plasma membrane, endoplasmic rediculum 
(ER) membrane, and Golgi membrane (16, 17, 51). This process is accomplished by
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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FIG. 1. Ras signal transduction pathway. Activated Ras protein (GTP-Ras) transfers 
signals through Raf, MEK, and MAP kinase protein, which then enter the nucleus and 
activate transcription factors of different genes (27, 55).
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a series of post-translational modifications, including three steps: prenylation in the 
cytosol, protease digestion, and methylation. The prenylated product is a substrate for 
additional modifications: the terminal three amino acids are proteolyzed by enzymes to 
generate a new C terminus and the new C terminus is carboxymethylated on the ER by 
prenylcysteine carboxyl methyltransferase (pcCMT) (17, 42). N-Ras and H-Ras are 
further modified with palmitate moieties that are attached to one or two cysteines just 
upstream of the CAAX motif (17, 59). In the case of K-Ras, a polybasic sequence near 
the C terminus allows stable interaction with anionic phospholipids at the inner leaflet of 
the plasma membrane (2, 17). The first and rate-limiting step is prenylation that increases 
the hydrophobicity of Ras protein.
RHO PROTEINS AND ASSOCIATED PATHWAY
The Rho family of proteins in mammals comprises several members including 
RhoA, RhoB, RhoC, Racl, Rac2, and Cdc42. Rho proteins transduce signals from plasma 
membrane receptors and control many cell functions requiring the assembly and 
organization of the actin cytoskeleton, such as those involved in cell polarity, motility, 
adhesion, cellular transformation, and apoptosis (5,21, 36). The means by which 
prenylation affects interaction with membrane targets and/or regulatory proteins remain 
largely unknown.
Several features distinguish RhoB from other Rho proteins (24): first, its cellular 
localization in early endosomes and prelysosomal compartments is different from other 
members of the Rho protein family. Secondly, RhoB is an immediate early response gene 
that is induced by platelet-derived growth factor (PDGF), transforming growth factor-a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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(TGF- a), the non-receptor tyrosine kinase v-Src, and ultraviolet irradiation in fibroblasts. 
Whether RhoB is also an immediate early response gene in human cancer cells is not 
known. Third, RhoB mRNA and protein levels turn over much more rapidly (half-lives of 
20 and 120 minutes, respectively) (42) than other GTPases, which typically have half- 
lives on the order of 24 hours (5, 33). Therefore, although RhoA and RhoB share 90% 
amino acid sequence homology, their physiological functions are predicted to be distinct. 
The level of RhoB is maximal during the S phase of DNA synthesis and declines at S/G2- 
M transition. Finally, Rho proteins are singly geranylgeranylated with the exception of 
RhoB and RhoE. The latter two proteins can be either famesylated or geranylgeranylated 
(4, 5).
RhoA is located primarily in the cytosol, with a small fraction being detected in the 
plasma membrane (17). A large number of GTPase activating proteins (GAPs) can 
stimulate the intrinsic GTPase activity o f RhoA. RhoA regulates signal transduction 
pathways linking plasma membrane receptors to the assembly of focal adhesion and actin 
stress fibers. The nucleotide sequence of the rhoA gene predicts a protein of 193 amino 
acid residues. The molecular weight of RhoA is 21,769 daltons. The amino acid sequence 
of RhoA protein is 30% identical to H-Ras protein and differs from RhoB protein at the 
amino acid position 29. The protein contains four highly conserved regions required for 
binding guanine nucleotide and has a C-terminal CAAX box, -CLVL, which is the signal 
for post-translational modification (17). A geranylgeranyl group is present at the carboxy 
terminus after post-translational modification. CAAX boxes ending in leucine are 
substrates for geranylgeranylation but not famesylation. Post-translationally modified 
RhoA, either GDP- or GTP-bound, will form a complex with Rho-GDI (GDP
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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dissociation inhibitor) and this complex is insensitive to GAP proteins. Inhibition of 
RhoA in SWISS 3T3 cells has been reported to block the cell cycle in G1 (72).
CYCLIN KINASE INHIBITOR P21/WAF1/CIP1
The tumor suppressor p53 transcriptionally activates a number of genes including the 
WAF1/CIP1 gene. The activation of WAF1/CIP1 by p53 appears to be key to the action 
of p53 as a tumor suppressor. The WAF1/CIP1 gene promoter contains a p53 response 
element. This gene encodes a 21-kD protein that binds cyclin dependent kinases (CDKs) 
and arrests cells in G1 or G2 phase of cell cycle (54, 62).
The 21-kD protein of the WAF1 gene is found in a complex involving cyclins,
CDKs, and proliferating cell nuclear antigen (PCNA) in normal cells but not transformed 
cells and appears to be a universal inhibitor of CDK activity. One consequence of 
p21/WAFl binding to and inhibiting CDKs is the prevention of CDK-dependent 
phosphorylation and subsequent inactivation of the retinoblastoma (Rb) protein that is 
essential for cell cycle progression (31). P21/WAF1 is, therefore, a potent and reversible 
inhibitor of cell cycle progression at both the G1 and G2 check points, presumably to 
allow sufficient time for DNA repair to be completed (26, 31).
PROTEIN FARNESYLTRANSFERASE AND PRENYLATION
Prenylation represents one of the most common lipid modifications of proteins.
Some of the known substrates for prenylation include all p21 Ras proteins, nuclear lamin 
A and lamin B, transducin y-subunit, Ras related Rho and Rac proteins, and y-subunits of 
heterotrimeric G proteins (8, 23, 25, 28, 75). Protein prenylation involves C-terminal
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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addition of C15 (famesyl) or C20 (geranylgeranyl) isoprenoids (Fig. 2). Both isoprenoids 
are intermediates in cholesterol biosynthesis. Protein prenylation reactions are carried out 
by one of three enzymes in the cell: famesyltransferase (FT or FTase), 
geranylgeranyltransferase type I (GGT-I or GGTase-I), or geranylgeranyltransferase type 
II (GGT-II, GGTase-II or RalbGGT). FT and GGT-I are related heterodimeric enzymes 
that share a common a-subunit. Prenylation at the carboxyl-terminal residues of proteins 
terminating with a CAAX sequence (where C is cysteine, A is an aliphatic acid and X is 
any amino acid) involves attachment of either famesyl (Cl 5) or geranylgeranyl (C20) 
isoprenoids, which can facilitate the integration of the protein into membranes (25). 
Famesyltransferase prefers the C-terminal amino acid to be either serine or methionine 
for famesylation, while leucine is the residue preferred by GGTase-I (19). Ki-Ras4A, Ki- 
Ras4B, N-Ras, and RhoB proteins can be either famesylated or geranylgeranylated, 
whereas H-Ras proteins are singly famesylated and RhoA proteins are singly 
geranylgeranylated (47, 60, 65, 67).
FTase is a heterodimer consisting of a 379-residue a-subunit (44-kD) and 437- 
residue zinc-containing P-subunit (48-kD) (20, 48, 49, 66). Both subunits are organized 
as a-helical secondary structures (Fig. 3). The a-subunit is composed of seven pairs of 
antiparallel a-helices folded into a crescent shaped structure. The P-subunit forms an 
unusual two layer a-helical barrel. The a-subunit is a right-handed superhelix based on 
seven copies of a helix-tum-helix repeat. The a-subunit of the human famesyltransferase 
can be phosphorylated by type I TGF-P receptor, and the phosphorylation has been 
suggested to serve a regulatory purpose. The P-subunit is a a-helical barrel open at one 
end and plugged at the other by a turn in the chain at residues 398-402 near the C-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
terminus. The active site containing Zn is located on the inside of the barrel near its upper 
end, where it is coordinated by the side chains of Asp297|3, Cys299p, and His362(3. The 
other notable feature of the barrel is its hydrophobic interior surface: the hydrophobic 
character of the active site fits well with the hydrophobic nature of both famesyl 
diphosphate and peptides such as CVIM.
Sequence differences between the rat and human FTase are on the surface of the 
enzyme away from the active-site Zn and in the interior of the barrel. This fact, together 
with the observation that the rat and human enzymes are closely related with 93% 
identity over 379 residues for the a-subunits and 97% identity over 437 residues for the 
p-subunits, suggests that the structure of the rat enzyme will be useful for dmg design 
efforts.
The a-subunit contacts the P-subunit barrel around half its circumference at the upper 
open end of the barrel (66). This arrangement places several residues of the a-subunit 
near the active-site Zn. In particular, the side chains of Lysl64a and His201a contribute 
to the formation of two anion binding sites 6.7A and 7.5 A from the Zn. His248P, 
Lys294p, Lys353p, Lys356P, and Arg29ip also contribute to the formation of the two 
binding sites. The proximity of these sites to the active-site Zn as well as their highly 
charged character suggest that they represent part of the binding site for the diphosphate 
moiety of the substrate famesyl diphosphate. The involvement of residues from both 
subunits is consistent with the observation that neither subunit alone is capable of binding 
FPP. Thus, both subunits would appear to have a role in binding and orienting the leaving 
group of FPP appropriately for catalysis.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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The FTase reaction can be summarized as (22, 23):
FTase
Protein-CAAX + FPP ------^------ ► Protein-F + PPi4 -------------
FARNESYLTRANSFERASE INHIBITORS AND CURRENT MODELS OF FTI 
MECHANISMS
Three major groups of famesyltransferase inhibitors (FTIs) have been developed (27, 
73). The first group is molecules derived via peptidomimetic approches, CAAX 
peptidomimetics, such as FTase inhibitor II (Calbiochem) and FTI 277 (Calbiochem). 
These compounds inhibit the isolated enzyme at nanomolar concentrations, but none of 
them have been developed further as clinically usable anticancer drugs. The second group 
is heterocyclic FTIs (R115777, SCH66336) that compete for the CAAX peptide binding 
site of FTase, not only inhibiting the isolated FTase at nanomolar concentrations, but also 
have demonstrated cytotoxic activity in vitro and in vivo in tumor cell lines with and 
without ras gene mutations (10). The third group is the FPP competitive compounds, 
such as FPT inhibitor II (CalBiochem) and FPT inhibitor III (Calbiochem), which inhibit 
the isolated enzyme FTase at nanomolar concentration and inhibit the growth of tumors 
produced by H-Ras transformed NIH/3T3 cells.
Ras plays a crucial role in cellular signal transduction pathways. The first and most 
critical post-translational modification of Ras is famesylation catalyzed by the FTase. 
Consequently, inhibitors of FTase have been proposed as potential agents for treating 
cancers in which Ras plays a pivotal role (27, 40, 70, 71).









FIG. 2. Prenylation of cellular proteins. Some proteins such as H-Ras and Lamin B are 
modified with the 15-carbon famesyl group, some such as RhoA contain the 20-carbon 
geranylgeranyl group, and some such as Rab proteins contain two geranylgeranyl groups. 
In all cases, the prenyl groups are at the C-terminus of the protein, and the a-carboxyl 
group is often methylated.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
FIG. 3. Structure of famesyltransferase. The X-ray diffraction structure of the FTase 
was obtained from the Brookhaven National Library Protein Data Bank. The a-subunit is 
composed of seven pairs of antiparallel a-helices folded into a crescent shaped structure 
(Top); the P-subunit forms an unusual two layer a-helical barrel (Bottom)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Although FTIs were originally developed as a Ras-targeted therapy, it currently 
appears that inhibition of Ras famesylation cannot account for all of the actions of the 
compounds (27, 41, 42, 43). First, FTIs do not require the presence of the activated, 
mutant Ras protein to produce anti-tumor effects. In other words, the susceptibility of 
human tumor cell lines to FTIs is not correlated with Ras mutation status. Secondly, the 
Ki-ras4B isoform, the predominant isoform mutated in human cancers, can undergo 
geranylgeranylation catalyzed by GGT-I when cells are treated with FTIs (67, 76). Thus, 
tumors bearing the mutant Ki-ras4B isoform should be resistant to FTIs; however, some 
tumors bearing Ki-ras4B mutations are clearly responsive to FTI treatments. Thirdly, the 
relative lack of cytostatic effects of FTIs on normal cells is curious, because Ras is 
required for the proliferation of normal cells. Furthermore, the kinetics of phenotypic 
reversion induced by FTI treatment are in many cases simply too rapid to be explained by 
loss of Ras function through inhibition of its famesylation. The reversion process occurs 
largely within 24 hours of cell treatment. FTIs only inhibit the production of newly 
synthesized Ras. The Ras protein is quite stable with a half-life of ~24 hours. Thus by the 
time reversion is complete, steady-state levels of famesylated Ras are only reduced by 
approximately 50%. Finally, even though in vivo tumors seem to regress completely, 
cessation of FTI treatment leads to a rapid return of tumors. Tumor persistence would 
require continuous long-term FTI treatment that could increase the likelihood of side 
effects and drug resistance. Prendergast and his research team in the Wistar Institute 
suggested that cell growth inhibition by famesyltransferase inhibitors is mediated by gain 
of geranylgeranylated RhoB (41, 42, 43, 56, 57).
RhoB has been implicated as an FTI target for several reasons (15): 1) RhoB is a
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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substrate for FTase, and FTIs inhibits its famesylation resulting in decreased RhoB-F and 
increased RhoB-GG. Geranylgeranylated forms of RhoB (RhoB-GG) accumulate in 
drug-treated cells because of the action of geranylgeranyl transferase-I which is 
unaffected by FTI; 2) The short half-life of RhoB coincides better than that of Ras with 
regard to the kinetics of the reversal of transformation of FTI; 3) The cell cycle kinase 
inhibitor p21 /WAF1/CIP1 is induced in cells and cell growth is inhibited when they are 
treated with FTIs; 4) The loss of RhoB-F and the gain of RhoB-GG associated with 
stress-fiber formation is compatible with anchorage-dependent growth, but not with 
anchorage-independent growth. For example, if Ras-transformed cells are cultured in 
suspension, where cell-cell but not cell-substratum attachment is possible, then FTIs 
induce massive apoptosis instead of reversion. Taken together, Chen’s results (15) 
support the conclusion that alteration of RhoB prenylation is both necessary and 
sufficient to the FTI mechanism in malignant cells. Both RhoB-F and RhoB-GG induce 
apoptosis, inhibit oncogenic signaling, and suppress transformation in vitro and in vivo 
(15).
The Rho GTPases are essential for Ras-induced oncogenic transformation (7, 52,
62), and activated Rho acts synergistically with activated Raf in cell transformation. Raf, 
with activated serine/threonine kinase activity, sends positive signals down a kinase 
cascade (the mitogen-activated protein kinase pathway) and prompts cells to move 
through the G1 phase of the cell cycle towards S phase of cell cycle. Excessive signaling 
from Ras/Raf induces p21/WAFl/CIPl and blocks entry into S phase. Rho A overcomes 
the cell-cycle block by suppressing expression of p21 /WAF1/CIP1 (52, 62) (Fig. 4).
Although some evidence showed the involvement of RhoB in the anti-tumor activity
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of FTIs (15, 42), direct evidence implicating RhoB in the mechanism of action of FTIs in 
human tumors is lacking. The roles of RhoB, RhoA, and p21/WAFl/CIPl in cellular 
mechanism of FTI anticancer activity have not been determined.
ARGLABIN-DIETHYLAMINOHYDROCHLORIDE
The guaianolide arglabin, a sesquiterpene lactone extracted from Artemisia 
myriantha, is used in Chinese medicine for the treatment of menorrhagia and 
inflammatory diseases (13, 32, 35, 50). Arglabin is a registered anticancer compound in 
the Republic of Kazakstan (1 ,3 ,9 , 63). Over 200 patients with a variety of cancers have 
been treated with this compound and generated very promising results and few side 
effects. The water soluble dimethylaminohydrochloride derivative of arglabin (arglabin- 
DMA) was used in current anti-tumor treatments and in this study. The formula weight of 
arglabin-DMA is 327.85 daltons and the structure of arglabin-DMA is shown in Figure 5. 
According to previous research on sesquiterpene lactones (1, 3, 63), arglabin is derived 
from trans-famesyl diphosphate by cyclization, rearrangements, and oxidation.
Shaikenov’s studies showed that arglabin-DMA inhibits the incorporation of 
famesylpyrophosphate into H-Ras protein by famesyltransferase with the 50% inhibition 
concentration (IC50) of 25 pM (63, 64). The phosphorylated form of arglabin-DMA 
competitively inhibits the binding of famesylpyrophosphate to famesyltransferases 
according to their in vitro kinetic studies (63, 64). Their in vitro studies suggested that 
arglabin-DMA inhibited post-translational modification of Ras protein in cells. Arglabin- 
DMA inhibits anchorage-dependent proliferation of neuroblastoma (NB) cells with IC50 
of 10 pg/ml (30.5 pM) and inhibits anchorage-independent growth of NB and Kirsten







FIG. 4. Schematic diagram of Ras, RhoA, and p21/WAFl/CIPl proteins in relation to 
the cell cycle (52, 62).
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FIG. 5. Structure of arglabin-dimethylamino (arglabin-DMA).
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MSV transformed normal kidney (KNRK) cells with the same IC50 (64). Soft-agar 
colony formation assay of H-Ras transformed cells showed an IC50 of 2 (ig/ml (6.1 pM). 
The focus of Shaikenov’s research was to determine whether arglabin-DMA is suitable 
for treatment of ras related malignancies.
PURPOSE OF THIS STUDY
The primary objective of this study was to better understand the cellular mechanism 
of arglabin-DMA cytotoxic effects on tumor cells. Two general hypotheses were 
examined in this study: (1) that arglabin-DMA inhibits protein famesylation in Ras 
transformed cells, and (2) that the cytotoxic activity of arglabin-DMA on Ras 
transformed cells is primarily derived from famesylation inhibition of Ras protein and/or 
Rho protein, and effects on cyclin kinase inhibitor p21/WAFl/CIPl. Three specific aims 
were addressed:
Determination of famesvltransferase inhibitory activity of arglabin-DMA using 
famesvltransferase expressed in vitro or produced in transformed cells.
Even though arglabin-DMA is a possible derivative of famesylpyrophosphate (1,3,
63), which is a substrate of famesyltransferase, and has structural similarity with cellular 
polyprenols, direct evidence of arglabin-DMA as a famesyltransferase inhibitor was 
lacking. The famesyltransferase assay, using arglabin-DMA and famesyltransferase 
expressed in vitro, has not been performed previously. One purpose of this study was 
therefore to determine whether in vitro famesyltransferase activity was inhibited by 
arglabin-DMA.
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Arglabin-DMA itself may not inhibit famesyltransferase activity. However, a 
derivative of arglabin-DMA such as phosphorylated arglabin-DMA in cells may inhibit 
famesyltransferase activity. Shaikenov’s studies showed that arglabin-DMA was 
phosphorylated intracellularly and this complex competitively inhibited binding of 
famesylpyrophosphate to famesyltransferase, thus inhibiting famesylation o f Ras protein 
(63, 64). To further determine whether arglabin-DMA or its derivative inhibit 
famesyltransferase activity in cells, investigation of famesyltransferase activity of cell 
lysate generated from cells treated with arglabin-DMA was appropriate. The present 
study addressed the hypothesis that arglabin-DMA inhibits protein famesylation in Ras 
transformed cells.
Determination of the inhibitory effects of arglabin-DMA on famesylation of Ras 
proteins in transformed cells.
Currently, putative FTIs anticancer activity through their effects on oncoproteins is 
still speculative. FTIs were originally developed as a Ras-targeted therapy, since the most 
frequently detected alterations in oncogenes of human cancers are mutations in the ras 
family of oncogenes, and the most critical post-translational modification of Ras is 
famesylation catalyzed by FTase (27, 45). H-Ras proteins are singly famesylated and K- 
Ras protein can be either famesylated or geranylgeranylated. The exact effects of 
arglabin-DMA on H-Ras and K-Ras proteins have not been elucidated. The present study 
investigated the effects of arglabin-DMA on H-Ras famesylation and K-Ras prenylation.
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Determination of the effects of arglabin-DMA on Rho protein prenvlation and cvclin 
kinase inhibitor p21/WAFl/CIPl production in transformed cells.
RhoB protein can be either famesylated or geranylgeranylated through post- 
translational modification. If arglabin-DMA reduces famesylation of RhoB by inhibiting 
famesyltransferase activity, more translated RhoB protein is available for 
geranylgeranylation, thus more substrate (GGP) and enzymes (GGT-I/GGT-II) are 
utilized for RhoB geranylgeranylation. In addition, the half-life of RhoB is about 2 hours, 
while that of RhoA is about 24-31 hours, depending on cell type. The rate of RhoB 
production is much faster than RhoA. Thus, the total post-translational modification of 
RhoB might be kept at the same level. RhoA is singly geranylgeranylated. The 
availability of substrates (GGP) and enzymes (GGT-I/GGT-II) for geranylgeranylation 
can be limiting due to increased usage by RhoB protein. The reduction of 
geranylgeranylated RhoA may decrease the regulatory inhibition of cyclin kinase 
inhibitor p21/WAFl/CIPl (Fig. 4). Thus, p21/WAFl/CIPl protein could be expressed 
and inhibit transformed cells moving from G1 to S phase of cell cycle.
The effects of arglabin-DMA on prenylated RhoB protein, geranylgeranylated RhoA 
protein, and cyclin kinase inhibitor p21/WAFl/CIPl were investigated. The present 
study addressed the hypothesis that the cytotoxic activity of arglabin-DMA on Ras 
transformed cells is primarily derived from famesylation inhibition of Ras protein and/or 
Rho protein, and effects on cyclin kinase inhibitor p21/WAFl/CIPl.




Arglabin-dimethylaminohydrochoride (arglabin-DMA) was a gift from Dr. 
Shaikenov of NuOncology Labs, Inc. Arglabin-DMA is a water soluble form of arglabin 
[1(R), 10(S)-epoxy-5(S), 7(S)-guaia-3(4), ll(13)-dien-6, 12-olide], a sesquiterpene y- 
lactone isolated from Artemisia glabella (64). The formula weight of arglabin-DMA is 
327.85. The structure of arglabin-DMA is shown in Figure 4. Lyophilized arglabin-DMA 
was dissolved in isotonic saline to make various concentrations of arglabin-DMA used 
for the experiments reported here.
Other known FTIs were purchased from Calbiochem. FPP competitive compounds 
FPT inhibitor II (Calbiochem 344152) and FPT inhibitor III (Calbiochem 344154) are 
phosphonic acids. They are both potent and selective inhibitors of FTase (IC50 = 75 nM). 
They also inhibit Ras famesylation in whole cells by 90% at 25 to 250 pM. FTI-277 
(Calbiochem 344555) and FTase inhibitor II (Calbiochem 344512) are CAAX 
peptidomimetics. They both selectively inhibit FTase with IC50 of 50 nM. FTI-277 
inhibits H-Ras processing in whole cells with IC50 of lOOnM. It is also highly effective 
and selective in disrupting constitutive H-Ras-specific activation of MAP kinase. 
Lyophilized FTIs were dissolved in isotonic saline to make various concentrations for the 
following experiments.
MOLECULAR MODELING
The famesyltransferase X-ray diffraction structure consisting of atomic coordinates
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of the binary complex of FTase and FPP was taken from the Brookhaven National 
Library Protein Data Bank (PDB). The substrate-binding site of the enzyme was prepared 
by removing the FPP molecule from the complex. The 3-D molecular structures of all 
ligands were drawn based on the 2-D structure diagram with the Insight II software 
purchased from Molecular Simulation Inc. (MSI) using a Silicon Graphics computer. The 
intermolecular energy of FTase and various ligands were measured using the Insight II 
docking program from MSI (Fig. 5). First, the stable docking models were searched while 
covering all possible binding modes and ligand confirmations. The top ten possible 
orientations of a ligand to dock to the active site of FTase were found, and then the 
intermolecular energies between the ligand and FTase were calculated. Intermolecular 
energies consisted of van der Waals, electrostatic, and hydrogen bond interactions (18,
30, 53). The ligands used for intermolecular energy calculation were FPT inhibitor II,
FPT inhibitor III, FTI-277, FTase inhibitor II, FPP, arglabin-DMA, and phosphorylated 
arglabin-DMA.
CULTURE OF H-RAS TRANSFORMED NIH-3T3 CELLS (RAS/3T3 CELLS)
The Ras/3T3 cell line is a gift from Dr. Shaikenov of NuOncology Labs Inc. The 
control NIH/3T3 cell line (CRL-1658) was purchased from the American Type Culture 
Collection (ATCC) as a continuous cell line established from a NIH Swiss mouse 
embryo. Both cell lines were propagated in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% fetal bovine serum (FBS) and 4 mM of L-glutamine at 37 + 1 
°C in a CO2 incubator containing 5% CO2 and 95% air.
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FIG. 6. Affinity docking. The intermolecular energy between famesyl pyrophosphate 
(middle) and famesyltransferase (peripheral) was calculated using an affininty docking 
program (Insight II from Molecular Simulations, Inc.). One frame of the docking process 
(interaction of FPP and active site of FTase) was captured in the figure.
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Representative photos were taken using a digital camera (Olympus, DPI 1) attached 
to a phase contrast microscope (Olympus, CK40). Seven-day growth curves were 
generated for both cell lines. Cells were seeded at the same densities (5000 cells/cm ) on 
day 0, and viable cell numbers were counted each day for 7 days using the trypan blue 
exclusion method. Cell densities of both cell lines were calculated.
Suspension culture of Ras/3T3 cells was prepared by using poly (2-hydroxyethyl 
methacrylate) (poly-Hema or Poly-HEME) surface coated 6-well tissue culture plates 
(71). Each well was coated with 0.8 mL of 1.2% poly-HEME prepared in 95% of ethanol 
and allowed to air dry in a Class II laminar flow hood for 16-18 hours. Ras/3T3 cells 
were seeded in the coated plates at 20,000 cells per well density. The number of cells was 
counted each day for 6 days using the trypan blue exclusion method. Representative 
photos were taken using a digital camera attached to a phase contrast microscope.
IN  VITRO CYTOTOXICITY ASSESSMENT OF ARGLABIN-DMA
In vitro cytotoxicity assays were performed using the MTT (3-[4,5-dimethylthiazol- 
2-yl]-2,5-diphenyl tetrazolium bromide) based in vitro toxicology assay kit from Sigma 
(Cat# TOX-1). Mitochondrial dehydrogenases of viable cells cleave the tetrazolium ring, 
yielding purple formazan crystals that are dissolved in acidified isopropanol. The 
resulting purple solution is spectrophotometrically measured. An increase or decrease in 
cell number results in a concomitant change in the amount of formazan formed, 
indicating the degree of cytotoxicity caused by the test material.
Ras/3T3 cells were seeded at 5000 cells per cm2 in 96-well cell culture plates. After 
cells had grown to the mid-log phase, the cell culture media was replaced by various
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concentrations of arglabin-DMA (0, 0.1, 1, 10, 25, 50, andlOO pM) made with complete 
cell culture media containing 10% FBS and 4 mM of L-glutamine. For controls, cell 
culture media containing 10% FBS and 4 mM of L-glutamine without arglabin-DMA 
was introduced to cells. The cells were incubated in a 37°C incubator containing 5% 
C(V95% air for 72 hours. A minimum of three replicates was used for each test group 
and control. After incubation, the media in each well was replaced by RPMI-1640 
without phenol red (150 (ll/well) and MTT solution (15 (ll/well). The 96 well plates were 
incubated in a 37°C incubator containing 5% CC>2/95% air for 2 hours. Solubilization 
solution (150 pl/well) was added into each well after incubation to dissolve any formazan 
crystals formed in viable cells. The absorbency of the resulting solution was measured at 
a wavelength of 570 nm on a plate reader. The background absorbency was measured at a 
wavelength of 690 nm on a plate reader. The absorbency of viable cells was calculated by 
subtracting background absorbency from the absorbency of the resulting solution. The 
results were plotted on Excel worksheets and expressed as absorbency of the resulting 
solution generated from viable cells for each test group and control, or percentages of 
viable cells compared to the control. An increase or decrease in cell number resulted in a 
concomitant change in the amount of formazan formed, indicating the degree of 
cytotoxicity caused by the test material.
FARNESYLTRANSFERASE EXPRESSION AND PURIFICATION
Plasmid DNAs of human famesyltransferase a  and (3 subunits (gifts from Dr. 
Tomanoi of the University of California in Los Angeles) were used to express human 
FTase (Fig. 7 and Fig. 8). The construction of plasmid pMALc2-hFTa contained the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
25
ampicillin resistance sequence and malE, which encodes maltose-binding protein (MBP). 
The plasmid pGEXhFTP construct confered ampicillin resistance sequence and carried 
the glutathione S-transferase (GST) gene sequence. Both plasmid DNAs contained the 
same promoters for FTase and for induction by isopropyl-beta-D-thiogalactopyranoside 
(IPTG).
Plasmid DNAs for a  and P subunits of FTase were co-transformed into DH5a 
competent Escherichia coli (E.coli) cells by electroporation at 2.5 kV for 5 milliseconds. 
These E.coli cells were propagated and selected with a high concentration of ampicillin 
(200 |lg/mL). FTa and FTP gene transcription were induced with 1 mM IPTG at 37°C 
overnight. The cell pellets were resuspended in sonication buffer (lxPBS/lmM 
EDTA/lmM EGTA/ 0.1% Lubrol/ O.lmM DTT) containing protease inhibitor cocktail 
(Sigma, P8849) and sonicated on ice. After centrifugation, the supernatants were purified 
with glutathione beads by mixing on a rocker at 4°C for 2 hours. The protein was eluted 
with elution buffer containing glutathione and concentrated using centrifugal filters 
(Amicon, Centricon YM-100, MWCO 100 kilodalton). Protein concentrations were 
determined using the bicinchoninic acid (BCA) assay. The relative protein size was 
confirmed with electrophoresis on SDS-polyacrylamide gel stained with coomassie blue. 
The enzyme activity of expressed FTase was determined by the subsequent in vitro FTase 
assay.












FIG. 7. Plasmid map of pMAL. The construction of plasmid pMALc2-hFTa contained 
the ampicillin resistance sequence and malE gene, which encodes maltose-binding 
protein (MBP).

















FIG. 8. Plasmid map of pGEX. The plasmid pGEXhFTP construct contained 
ampicillin resistance sequence and the glutathione S-transferase (GST) gene sequence.
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IN  VITRO FTASE ASSAY USING FTASE EXPRESSED IN AN E.COLI 
EXPRESSION SYSTEM
FTase can transfer the famesyl group of famesylpyrophosphate (FPP) to protein 
substrates (such as lamin B or Ras protein) to generate famesylated protein and 
pyrophosphate. The in vitro FTase assay quantitates the amount of radio-labeled 
famesylated protein using radio-labeled FPP as a substrate (34, 74). The FTase activity 
was determined by measuring the incorporation of the 3H-famesyl group of 3H-FPP to the 
substrate peptide. The usage of radioactive materials and the experimental procedures 
were approved by the Radiation Safety Committee (RSC) of Old Dominion University 
(Norfolk, VA).
The Famesyltransferase Scintillation Proximity Assay (SPA) Kit was purchased from 
Amersham Life Science (TRKO 7010). Scintillation proximity assay uses 
fluoromicrospheres (yttrium silicate beads) coated with streptavidin (12, 34,46). Protein 
substrates were labeled with biotin. Famesylpyrophosphate was labeled with tritium (3H) 
that emits low energy radiation. During the FTase assay reaction, radioactively labeled 
famesylated-biotinylated-protein was generated relative to total famesyltransferase 
activity. When this product bound to the beads and, by its proximity, the emitted short- 
range electrons of the isotope excited the fluorophor in the bead. The light emitted was 
measured using a standard liquid scintillation counter. The enzymatic reaction was started 
by adding 20 pi of purified FTase (0.1 pg/pl) into 80 pi of assay buffer consisting of 
[3H]-FPP (120 nM), zinc chloride (100 pM), and biotin lamin-B peptide (0.5 pM). The 
tubes containing the combined reaction solutions were incubated at 37°C water bath for
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60 minutes. The assay was stopped by the addition of STOP/bead reagent into the 
reaction. The resulting solution was counted using a liquid scintillation counter.
A standard curve of FTase activity was generated using increasing amounts of cell 
protein (0.4-4 pg) produced from the FTase expression and purification procedures (Fig
9). Reactions without cell protein and reactions without the addition of arglabin-DMA 
were used as negative controls. Reactions using a known FTI, FPT inhibitor II 
(Calbiochem 344152) or FTase Inhibitor II (Calbiochem 344512) were used as positive 
controls. Various concentrations of arglabin-DMA were tested in FTase assays. The 
FTase enzymatic activity was expressed as the amount of radiolabeled famesylated 
protein per minute of reaction (pCi/min). The 50% inhibition concentration (IC50) of 
known FTIs and arglabin-DMA were determined. Various concentrations of radio- 
labeled FPP were used to determine the velocity of enzyme reaction (pmol/min). 
Lineweaver-Burk plots of known FTIs and arglabin-DMA were generated to show the 
type of inhibition of famesyltransferase.
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FIG. 9. Standard curve of FTase assay. Various amount of expressed and purified 
FTase (0.4 pg -  4 pg) was used for FTase standard curve generation. Generation of 3H- 
famesylated-biotin-lamin B peptide was measured by liquid scintillation counter.
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CELL LYSATE PREPARATION
An equal number of Ras/3T3 cells was seeded in T25 flasks. After cells had grown to 
the mid-log phase, various concentrations of arglabin-DMA (0.1, 1, 10, 50, and 100 pM) 
were introduced into cell culture media. Once the cells had been treated for 2 hours, 24 
hours, or 72 hours, the culture media were removed. Cells were washed with lx 
phosphate buffered saline (PBS) and removed from tissue culture flasks using lysis buffer 
containing sodium chloride (150 mM), magnesium chloride (5 mM), DTT (ImM), 
sodium phosphate (1 mM), triton X-100 (1%), sodium dodecylsulfate (0.05%), HEPES 
(50 mM), phenylmethylsulfonyl fluoride (1 mM), sodium vanadate (1 mM), aprotinin (10 
pg/mL), and leupeptin (10 pg/mL) (37, 38, 39, 45). Cell suspensions in lysis buffer were 
sonicated at 10 watts for a total of 60 seconds. After sonication, cell lysates were 
centrifuged at 10,000 relative centrifugal force (ref) for 10 minutes. The supernatants 
were transferred to new centrifuge tubes and used for experiments. Protein concentrations 
of cell lysates were quantificated using BCA assays. Samples with the equal amounts of 
cellular protein were utilized.
The negative control was the cell lysate generated from cells without arglabin-DMA 
treatment. The positive control was the cell lysate obtained from cells treated with known 
famesyltransferase inhibitor.
PROTEIN QUANTIFICATION
The BCA protein assay™ detects and quantitates total protein in samples by using 
reagents containing bicinchoninic acid (BCA). The purple-colored reaction product of 
this assay was formed by the chelation of two molecules of BCA with one cuprous ion,
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which generated from reduction of Cu+2 to Cu+1 by protein. Bovine serum albumin (BSA) 
ranging from 25 pg/mL to 750 pg/mL was used for standard curve generation. Linearity 
exists over the protein concentration range of 25 pg/mL to 750 pg/mL (R =0.9971, Fig.
10). The BCA protein assay was started by addition of 200 pi of working reagent which 
contained BCA and cuprous cation (Cu+2) to 25 pi of testing solution (such as cell lysate) 
in a 96-well assay plate. The plate was incubated at 37°C for 30 minutes, and the optical 
densities of the standard and test samples were measured at absorbency of 570 nm in a 
plate reader. The protein concentrations of the testing samples were calculated by 
comparing the optical density at 570 nm with the standard curve generated for each 
assay. A minimum of three replicates of each testing sample was used for every protein 
assay.
FTASE ASSAY USING FTASE PRODUCED IN H-RAS TRANSFORMED 
NIH/3T3 CELLS
The endogenous famesyltransferase activity was tested by an in vitro FTase assay. 
This in vitro FTase Assay uses cell lysate as a source of FTase (47, 57, 68, 69). The cell 
lysates were generated from Ras/3T3 cells incubated with various concentrations of 
arglabin-DMA for 2 hours, 1 day, or 2 days. Tritiated famesylpyrophosphate and Ras 
protein were used as the substrates. Tritiated famesylated Ras protein was generated in 
proportion to the FTase activity of the cell lysate.
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FIG. 10. Standard curve for BCA Assay. Bovine serum albumin (BSA) ranging from 
25 (ig/mL to 750 |4g/mL was used for standard curve generation. The absorbency of BSA 
was measured at 570 nm in a plate reader.
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The in vitro FTase assay was initiated by adding 5 (j.1 of cell lysate (15-20 jig protein) 
into 45 pi of assay buffer. The assay buffer contained H-Ras protein (100 nM), [3H]FPP 
(100 nM, 0.1 pCi), MgCl2 (5 mM), dTT (5 mM), and HEPES (50 mM), and the pH was 
adjusted to 7.5 with IN HC1 (47). The reaction was maintained at 37°C for 1 hour and 
stopped by adding 1M of ice-cold hydrochloride (HC1) prepared with ethanol. The 
resulting solution was filtered through GF/C filter paper and rinsed by 1 ml of ice-cold 
ethanol. The filter paper was dried in air and transferred into scintillation fluid. The 
radioactivity was measured by liquid scintillation counter.
Reactions without cell lysate were used as blank negative controls. Reactions using 
cell lysate generated from cells without arglabin-DMA treatment, and reactions using 
famesyltransferases expressed and purified through prokaryotic system were used as the 
other negative controls. Reactions using a known FTI were the positive controls. The 
nonspecific activity of the blank negative control was subtracted from the total 
radioactivity of each sample. The specific activity of each sample was calculated by 
dividing the radioactivity (counts per minute) by the amount of protein. The percentage 
of famesyltransferase inhibition of arglabin-DMA in cells was calculated by comparing 
the specific activity of each sample to the cell lysate negative control (without arglabin- 
DMA treatment). Three replicates were used for each test and control group. Dose- 
response curves for arglabin-DMA were generated.
GEL ELECTROPHORESIS
SDS-polyacrylamide gels (12% or 4-15%) were purchased from Bio-Rad. Precision 
pre-stained protein standards ranging from 10 to 250 kD (BioRad, 161- 0373) were used
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to assess the relative protein size and transfer efficiency. Equal amounts of sample buffer 
(BioRad, 161-0737) containing beta-mercaptoethinal and protein samples were mixed, 
then denatured in boiling water for 5 minutes and stored in wet ice until they were used. 
Thirty microliter samples were loaded into each well, and 200 volts of electricity was 
used to separate various sizes of proteins in samples. After 1 hour o f electrophresis in lx  
Tris-Glycine-SDS (TGS) running buffer (BioRad, 161-0772), the gel was ready for 
Coomassie blue staining or protein transfer.
COOMASSIE BLUE STAINING
The SDS-polyacrylamide gel was fixed in solution containing 50% methanol and 
10% acetic acid for 30 minutes. After removing fixing solution, the gel was stained with 
Coomassie blue stain (BioRad, R-250) and agitated at room temperature for 3 hours. 
Approximately 1 (ig of protein per band was needed for detection using Coomassie blue 
R-250 staining. The gel was destained with solution containing 5% methanol and 7% 
acetic acid overnight on an orbital shaker with slow agitation. A photo of the gel was 
taken after destaining process and used for documentation and analysis.
PROTEIN TRANSFER
SDS-polyacrylamide gels from electrophoresis were submerged in lx  transfer buffer 
containing 20% methanol and lx  Tris-Glycine buffer (BioRad, 161-0771) for 15 minutes. 
The proteins separated through electrophoresis were transferred to polyvinylidene 
difluoride (PVDF) membrane in lx  transfer buffer at 350 mA for 1 hour using Mini
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Trans-Blot Cell (Bio-Rad, 170-3930). The transfer efficiency was assessed by examining 
the prestained protein standard.
IMMUNOPRECIPITATION
Immunoprecipitation before electrophoresis was used to increase the sensitivity of 
Western blot (65, 67). Specific primary antibody (1 pg) was added to 1 mL of cell lysates 
according to various manufacturer instructions. After incubating the cell lysate at 4°C for 
2-4 hours, the antigen-antibody complexes were generated. ProteinG agarose beads (20 
pL) were introduced into cell lysate containing antigen-antibody (Ag-Ab) complexes.
The immunoprecipitation were performed on a rocker at 4°C overnight. Antigen-antibody 
complexes attached to agarose beads were separated from cell lysates by centrifugation at 
1,000 g for 5 minutes. The precipitates were washed with 1 mL of phosphate buffered 
saline (lx  PBS) 3-4 times. The final precipitates were resuspended in sample buffer 
(BioRad, 161-0737), denatured in boiling water for 5 minutes, and loaded into SDS- 
polyacrylamide gel for electrophoresis. Antibodies used for immunoprecipitation were 
listed in Table 1.
WESTERN BLOT
Following the protein transfer, non-specific protein binding sites were blocked by 
agitation PVDF membrane in blocking reagents containing 3% casein and 0.15% Tween- 
20 for 2 hours. The membrane was then incubated with a primary antibody specific to the 
antigen of interest for 2 hours with slow agitation at room temperature. After washing 
away unbounded antibody, the blot was incubated with a secondary antibody linked to
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horseradish peroxidase (HRP). Following washing unbounded secondary antibody, the 
blot was incubated in the Opt:i-4CN substrate for up to 30 minutes, or until the desired 
sensitivity was attained. The Opti-4CN detection system (Bio-Rad, 170-8235) uses 
colorimetric horseradish peroxidase substrate, 4-chloro-l-naphthol (4CN), which can 
generate the detection sensitivity of 100 pg. The primary and secondary antibodies used 
in this study are listed in Table 1.
SMALL GTPASE-PULL DOWN ASSAY
The EZ-Detect™ Ras Activation Kit (Pierce, 89855) and EZ-Dectect™ Rho 
Activation Kit (Pierce, 89854) were purchased from PIERCE. This assay quantitates the 
active Ras protein (or RhoA protein) by isolating them via their specific downstream 
effector Raf protein (or Rhotekin for RhoA protein). The Ras-binding domain (RBD) of 
Raf protein was expressed as a Glutathione-fusion protein (GST), which was used to pull 
down the active or GTP-bound Ras protein. The Rho-binding domain (RBD) of Rhotekin 
was expressed as GST protein as well, which was used to precipitate cellular GTP-bound 
RhoA protein. After immobilized bait protein (GST-RBD) was incubated with cell 
lysates at 4°C for 1 hour in the presence of a SwellGel Immobilized Glutathione Disc, 
GST-RBD of Rafl or GST-RBD of Rhotekin pulled down active Ras protein or active 
RhoA protein. The SwellGel Immobilized Glutathione Disc was washed 3 times with 400 
(iL of 1 xLysis/Binding/Wash buffer. The “interactors” were selectively eluted with 
sample buffer by boiling the samples at 95-100°C for 5 minutes. Samples were collected 
by centrifugation at 7,200 g  for 2 minutes and introduced into SDS-polyacrylamide gel to
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TABLE 1. List of antibodies used for immunoprecipitation (IP) and Western blot (WB)
Antigen Antibody for IP
FTase N/A
H-Ras Mouse anti-Ras IgG (89855b)
K-Ras Mouse anti-Ras IgG (89855)
RhoA Rabbit anti-RhoA IgG (scd-179)
Rho B Rabbit anti-RhoB Ig G(sc-180)
P21WAF1 Rabbit anti-p21 IgG (abe-7960)
Primary Antibody for WB




Rat anti-v-H-Ras (OPcl)  
Mouse anti-K-Ras (sc-30) 
Mouse anti-RhoA (sc-418) 
Mouse anti-RhoB (sc- 
8048)








341285: Antibody from Calbiochem-Novabiochem Corporation (San Diego, CA). 89855: Antibody 
from PIERCE Biotechnology, Inc. (Rockford, IL).C OP: Antibodies from Oncogene Research Products (San 
Diego, CA).d sc: Antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).e ab: Antibodies from 
Abeam Limited (Cambridgeshire, UK).
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separate different sizes of proteins. The pulled-down active Ras and Rho protein were 
detected by a Western blot.
DENSITOMETRY ANALYSES
The intensity of the bands from Western blot was determined by densitometry using 
the Quantity One system (4.6) from Bio-Rad according to the manufacturer instruction. 
Briefly, the images of blots were scanned and stored in a computer. The bands of interest 
were selected using Quantity One program. Values of maximum intensity (INT), 
minimum intensity (INT), mean (INT), standard deviation, volume area (mm2), density 
(INT/mm ), and background intensity (INT) were assessed and calculated using Quantity 
One program.
STATISTICAL ANALYSES
Each data point consists of at least 3 replicates in all statistical analyses. Linear 
regression analyses were used to derive standard curves. An analysis of variance 
(ANOVA) was used to determine the significant differences among all experimental 
groups. Two-sample t-tests were performed to compare the differences between any 2 
specific groups. A confidence level of 95% was considered to be statistically significant.
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RESULTS
IN VITRO CYTOTOXICITY OF ARGLABIN-DMA
Characterization of H-Ras Transformed NIH-3T3 Cells and NIH/3T3 Cells
Both Ras/3T3 cells and NIH/3T3 cells were propagated in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 10% fetal bovine serum and 4 mM of L-glutamine 
at 37 °C in a C 02 incubator containing 5% C 02/95% air. Photos of representative cell 
morphologies of NIH/3T3 cells and Ras/3T3 cells were taken using a digital camera 
attached to the microscope (Fig. 11). NIH/3T3 cells showed monolayer morphology 
when cells reached confluence (Fig. 11 A). Ras/3T3 cells showed cluster formation and 
loss of “contact inhibition” (piled up) in culture (Fig. 1 IB). Normal diploid mammalian 
cells, such as NIH/3T3 cells, have a phenomenon called density-dependent inhibition of 
growth or “contact inhibition”, which means the cell-cell contact stops cell replication 
(61). The transformed cells, such as Ras/3T3, not only have decreased density-dependent 
inhibition of growth, but also loss of anchorage dependence (Fig. 12 A). Ras/3T3 cells 
had grown in suspension culture where the plates were coated with poly-HEME (Fig. 
12B).
Viable cell numbers were counted using the Trypan Blue exclusion method for a 
continuous seven days after seeding 5,000 cells/cm on day 0. The seven-day growth 
curves showed that the number of NIH/3T3 cells plateau at 60,080 cells/cm (Fig. 13), 
while the number of Ras/3T3 cells plateau at 308,200 cells/cm2. Population doubling 
time (PDT) from day 1 to day 4 was 23.51 hours for NIH/3T3 cells and 17.45 hours for 
Ras/3T3 cells. The number of Ras/3T3 cells increased significantly for 5 days until the
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nutrients in culture media were exhausted. The number of NIH/3T3 cells increased for 4 
days until cells reached confluence.
In Vitro Cytotoxicity Assessment of Arglabin-DMA
Arglabin-DMA at concentrations of 0.1 pM, 1 pM, 10 pM, 50 |iiM, and 100 fiM 
were prepared with DMEM containing 10% FBS and 4 mM of L-glutamine. Equal 
numbers of Ras/3T3 cells and NIH/3T3 cells were seeded in 96-well plates. After 48 
hours of incubation at 37 °C in a CO2 incubator containing 5% of CC>2/95% air, the 
culture media was replaced by culture media containing various concentrations of 
arglabin-DMA. Cells incubated in medium alone were used as negative controls. Cells 
incubated with 5% sodium azide were used as a positive control. After 72 hours of 
incubation with arglabin-DMA, in vitro cytotoxicity assays were performed using the 
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) based in vitro 
toxicology assay kit from Sigma (TOX-1). An increase or decrease in cell number results 
in a concomitant change in the amount of formazan formed, indicating the degree of 
cytotoxicity caused by the test material. Absorbencies of viable cells were measured 
using a plate reader (Labsystems, MultiSkan Ascent).
The absorbency of the Ras/3T3 cell control (OD =1.014) was more than twice that 
of the NIH/3T3 cell control (OD = 0.4457) after 72 hours of incubation. Dose-response 
curves for arglabin-DMA were generated for both cell lines (Fig. 14). Concentrations of 
arglabin-DMA (pM) were plotted in logarithmic scale. A trend line was generated from 
the plot using percentage of growth inhibition (compared to the positive control cells 
without arglabin-DMA treatment) versus logarithmic scale of arglabin-DMA 
concentrations (pM)) (Fig. 15). Regression analysis showed 96% correlation between
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concentration of arglabin-DMA and percentage of growth inhibition. The 50% inhibition 
concentration (IC50) of arglabin-DMA for Ras/3T3 cells estimated from the plot was 
10.34 pM, and the IC90 was 79.28 pM. The concentration of arglabin-DMA used to 
inhibit half of Ras/3T3 cell growth was 10.34 pM, while the concentration of arglabin- 
DMA used to inhibit the same number of NIH/3T3 cells was more than 100 pM, 
approximately 10-fold greater than the concentration for Ras/3T3 cells.
THE EFFECT OF ARGLABIN-DMA ON FTASE ACTIVITY 
Binding Affinity of Arglabin-DMA and FTase
The X-ray diffraction structure of the FTase and FPP complex was taken from the 
Brookhaven National Library Protein Data Bank. The 3-D molecular structures of all 
ligands were drawn based on the 2-D structure diagram using the Insight II software. The 
intermolecular energy of FTase and various ligands were measured using the Insight II 
docking program (Appendix A).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
43
0.1mm
FIG. 11. Confluent Ras/3T3 cells and NIH/3T3 cells in culture. Figure 11A - 
monolayer of NIH/3T3 cells after reaching confluence. Figure 1 IB - Ras/3T3 cells 
formed clusters and loss of “contact inhibition” (piled up) in culture. All of the photos 
shown here were taken at lOOx magnification.
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FIG. 12. Growth of Ras/3T3 cells in suspension. Figure 12A - Ras/3T3 cells grown in 
poly-HEME coated tissue culture plates. Figure 12B - growth curve for Ras/3T3 cells 
grown in suspension in poly-HEME coated tissue culture plates. The photo shown here 
was taken at lOOx magnification.










0 1 2 3 4 5 6 7 8
day
FIG. 13. Growth curves of Ras/3T3 cells and NIH/3T3 cells. Viable cell numbers were 
counted each day for 7 days. The number of Ras/3T3 cells increased significantly for 5 
days until the nutrients in culture media were exhausted. The number of NIH/3T3 cells 
increased for 4 days until cells reached confluence.
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FIG. 14. Dose-response curves ofNIH/3T3 cells and Ras/3T3 cells to arglabin-DMA. 
Culture media containing various concentrations of arglabin-DMA (0.1, 1, 10, 50, or 100 
pM) were used to incubate with cells for 72 hours. The absorbencies obtained from MTT 
assays reflect the viable cell number for both cell lines, indicating the degree of 
cytotoxicity caused by the test material. For the Ras/3T3 cell control and NIH/3T3 cell 
control (not shown in this figure), the absorbency of viable Ras/3T3 cells (OD = 1.014) 
was more than twice as much as the absorbency of viable NIH/3T3 cells (OD = 0.4457).
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FIG. 15. Percentage Ras/3T3 cell growth inhibition by arglabin-DMA. A trend line was 
generated from the plot using percentage of growth inhibition (compared to the positive 
control cells without arglabin-DMA treatment) versus logarithmic scale of arglabin-DMA 
concentrations (pM). The 50% inhibition concentration (IC50) of arglabin-DMA for 
Ras/3T3 cells estimated from the plot was 10.34 pM, and the IC90 was 79.28 pM.
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The mean of the intermolecular energy of all ten possible frames and standard 
deviation for each pair of ligand and FTase were calculated and shown in Table 2. The 
difference in intermolecular energy was statistically significant between pairs of all seven 
ligands (Appendix B) (p < 0.05). The lower the intermolecular energy, the higher the 
binding affinity of ligand and FTase will be (18, 30). The intermolecular energy between 
arglabin-DMA and FTase (-46.97 kCal/mol) was significantly higher than the 
intermolecular energy between FPP and FTase (-60.8 kCal/mol) (p < 0.05) (Table 2), 
which means that arglabin-DMA was not able to compete for the FTase binding site with 
FPP. The intermolecular energy between FTase inhibitor II and FTase (-57.57 kCal/mol), 
the energy between phorsphorylated arglabin-DMA and FTase, and the energy between 
FTI-277 and FTase were not significantly different from the intermolecular energy 
between FPP and FTase (p > 0.05). Intermolecular energy between FPT inhibitor II and 
FTase and intermolecular energy between FPI inhibitor III and FTase were significantly 
lower than the intermolecular energy between FPP and FTase (p < 0.05). These results 
suggested that arglabin-DMA itself may not bind to FTase directly and arglabin-DMA 
itself is not a potent FTase inhibitor.
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TABLE 2. Intermolecular energy between FTase and various ligands
Ligands Intermolecular Energy (kCal/mol) Stdev
FPT Inhibitor II -82.19 12.16
FPT Inhibitor III -78.90 5.37
FTI-277 -65.93 10.26
Phosphorylated Arglabin-DMA -63.70 4.76
FPP -60.80 5.56
FTase Inhibitor II -57.57 7.31
Arglabin-DMA -46.97 4.62
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The Effect of Arglabin-DMA on Expressed and Purified FTase Activity 
Verification o f the Expressed and Purified FTase
Human FTase a  and p subunits were expressed in competent E.coli cells, purified 
through glutathione affinity chromatography and concentrated by centrifugation using 
centrifugal filters with 100 kiilodalton molecular weight cutoff (MWCO). The protein 
concentration of the purified FTase was determined by BCA protein assay. The relative 
protein size was confirmed by electrophoresis of the purified protein on SDS- 
polyacrylamide gel stained with Coomassie blue. Coomassie blue staining showed two 
separate bands: one band had a relative size of 90 kD the second band with a relative size 
of 70 kD when compared to the ladder (Fig. 16). The relative protein size of MBP-FTa 
should be 74.1 kD, which included MBP (29.7 kD) and the FT a-subunit (44.4 kD). The 
relative size of GST-FT|3 should be 90.2 kD, including GST (42 kD) and the FT 0- 
subunit (48.8 kD).
The enzymatic activity of the expressed and purified FTase was determined by in 
vitro FTase assay. The standard curve of FTase activity was generated using increasing 
amounts of cellular protein (0.4-4 (0,g) (Fig. 9). Generation of H-famesylated-biotin- 
lamin B peptide was measured by liquid scintillation counter (microcurie/min). Linearity 
existed over the range of 0.4 |ig to 4 (ig of purified protein (R = 0.9956, Fig. 9). Two 
micrograms of cellular protein was chosen to use for the following in vitro FTase assays.
FTase Assay using expressed and purified FTase
The FTase activity was determined by measuring the incorporation of the 3H-famesyl 
group of 3H-FPP to the substrate peptide, lamin-B. Various concentrations of arglabin-
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DMA (50, 100, 1000, 2000, 4000, and 8000 pM), FPT inhibitor II (1, 10, 50, 100, 1,000, 
5,000, and 10,000 nM), or FTase inhibitor II (0.01, 0.05, 0.1, 0.5, 1, 5, and 10 pM) were 
tested in FTase assays. The FTase enzymatic activity was expressed as the amount of 
radiolabeled famesylated protein per minute of reaction (pCi/min). Dose-response curves 
for arglabin-DMA, FPT inhibitor II, and FTase inhibitor II are shown in Figure 17,
Figure 19, and Figure 21. Percentages of FTase inhibition by various compounds were 
calculated by comparing the FTase activity to the no-treatment control. Trend lines were 
generated from percentage inhibition plots (Fig. 18,-Fig. 20, Fig. 22). The 50% inhibition 
concentration (IC50) of known FTIs and arglabin-DMA were estimated from the 
equation of the linear regression.
FPT inhibitor II is a phosphonic acid, an FPP analogue, which competes for the FPP 
binding site of FTase. FTase assay showed significant inhibition at nanomolar 
concentrations of FPT inhibitor II (Fig. 17). Linearity exists over FPT inhibitor II 
concentrations ranging from 10 nM to 1000 nM (R2 = 0.975, Fig. 18). The IC50 of FPT 
inhibitor II calculated from the equation of the linear regression was 119 nM. FTase 
inhibitor II is a pepidomimetic inhibitor of FTase, which competes for the protein binding 
site of FTase. FTase assays indicated significant inhibition of FTase activity at







FIG. 16. Coomassie blue staining of expressed and purified FTase. The relative protein 
size of MBP-FTa was 74.1 kD, which included MBP (29.7 kD) and FT a-subunit (44.4 
kD). The relative size of GST-FTJ3 was 90.2 kD that included GST (42 kD) and FT 13- 
subunit (48.8 kD).
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micromolar concentrations of FTase inhibitor II (Fig. 19). The IC50 of FTase inhibitor II 
calculated from the equation of the linear regression of the percentage inhibition plot was 
5.09 pM (R = 0.972, Fig. 20). FTase assay using various concentrations of arglabin- 
DMA showed that FTase activity was inhibited by arglabin-DMA at millimolar 
concentrations (Fig. 21). Linearity exists over the arglabin-DMA concentration ranging 
from 500 |iM to 8000 pM (R2 = 0.9776, Fig. 22). The IC50 for Arglabin-DMA calculated 
from the equation of the linear regression was 2.9 mM.
Lineweaver-Burk Double Reciprocal Plot o f  Arglabin-DMA and Known FTIs 
The Lineweaver-Burk plot shows 1/v (velocity) versus 1/[S] (substrate 
concentration), which gives a straight line with a slope of Km/Vm and a y-intercept of -  
1 /Km. Thus, Vm (maximum velocity) and Km (Michaelis constant) can be obtained from 
the plot. The Michaelis constant is an indication of the relative affinity of the enzyme for 
the substrate (51, 58). The lower the Michaelis constant, the higher affinity between 
substrate and enzyme. Various concentrations of tritium-labeled FPP (2, 4, 8, and 16 pM) 
were used to determine the velocity of enzyme reaction (pmol/min). The Lineweaver- 
Burk plot of FPT inhibitor II was generated from FTase assays using various 
concentrations of tritium-labeled FPP and three concentrations of FPT inhibitor II (0 nM, 
10 nM, 100 nM) (Fig. 23). The Lineweaver-Burk plot of FTase inhibitor II was generated 
from FTase assays using various concentrations of tritium-labeled FPP and three 
concentrations of FTase inhibitor II (0 nM, 500 nM, 5,000 nM) (Fig. 24). The 
Lineweaver-Burk plot of arglabin-DMA was generated from FTase assay using various







0 2000 4000 6000 8000 10000 12000
concentration of FPT inhibitor II (nM)
FIG. 17. Dose response curve of FPT inhibitor II. Various concentrations of FPT 
inhibitor II (1, 10, 50, 100, 1,000, 5,000, and 10,000 nM) were used for FTase assay. 
FTase activity was reduced significantly when the concentration of FPT inhibitor II was 
between 10 nM tol,000 nM.
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FIG. 18. Percentage of inhibition of FTase activity by FPT inhibitor II. A trend line 
was generated from the plot using percentage of inhibition versus logarithmic scale of 
FPT inhibitor II concentrations (nM). Linearity exists over FPT inhibitor II concentration 
ranging from 10 nM to 1000 nM (R2 = 0.975). IC50 of FPT inhibitor II calculated from 
the equation of linear regression was 119 nM.
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FIG. 19. Dose response curve of FTase inhibitor II. Various concentrations of FTase 
inhibitor II (0.01, 0.05, 0.1, 0.5, 1, 5, and 10 pM) were used for FTase assay. FTase 
activity was reduced significantly when the concentration of FTase inhibitor II was 
between 1 pM to 10 pM.
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FIG. 20. Percentage of inhibition of FTase activity by FTase Inhibitor II. A trend line 
was generated from the plot using percentage of inhibition versus logarithmic scale of 
FTase inhibitor II concentrations (nM) (R2 = 0.972). IC50 of FTase inhibitor II calculated 
from the equation of the trend line was 5.09 pM.
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FIG. 21. Dose response curve of arglabin-DMA. Various concentrations of FTase 
inhibitor II (50,100,1000,2000,4000, and 8000 pM) were used for FTase assay. FTase 
activity was reduced significantly when the concentration of arglabin-DMA was between 
1 mM and 8 mM.
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FIG. 22. Percentage of inhibition of FTase activity by arglabin-DMA. A trend line was 
generated from the plot using percentage of inhibition versus logarithmic scale of 
arglabin-DMA concentrations (pM). Linearity exists over arglabin-DMA concentration 
ranging from 100 pM to 8,000 pM (R2 = 0.976). The IC50 of arglabin-DMA calculated 
from the equation of linear regression was 2.9 mM.
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concentrations of tritium-labeled FPP and three concentrations of arglabin-DMA (0 pM,
1 pM, 4 pM) (Fig. 25).
Lineweaver-Burk double reciprocal plots of 1/v versus 1/[S] showed that Vm (0.75 
pmol/min) were nearly identical for three different concentrations of FPT inhibitor II 
(Fig. 23). Km changed at different FPT inhibitor concentrations. The plot indicates 
competitive inhibition of FTase by FPT inhibitor II, which means that FTI inhibitor II 
competes with the FPP for binding to the active site of FTase. The Lineweaver-Burk 
double reciprocal plot of FTase inhibitor II showed a constant slop (Km/Vm), but both 
Km and Vm changed with various concentrations of FTase inhibitor II. These results 
indicated that FTase inhibitor II was an uncompetitive inhibitor of FTase (Fig 24), which 
means FTase inhibitor II binds to the FPP-FTase complex, not FTase. The Lineweaver- 
Burk double reciprocal plot of arglabin-DMA was more like the double reciprocal plot of 
FTase inhibitor II with a contant slope (Km/Vm) (Fig. 25). This suggests that arglabin- 
DMA may bind to FPP-FTase complex and inhibits FTase activity at higher 
concentrations than FPT inhibitor II and FTase inhibitor II.
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FIG. 23. Lineweaver-Burk double reciprocal plots of FPT inhibitor II. FTase-catalyzed 
reaction velocity (1/v) versus substrate concentration (1/[S]) using various concentrations 
of FPT inhibitor II (0 nM, 10 nM, 100 nM). Vm was constant for three different 
concentrations of FPT inhibitor II (0.75 pmol/min). Km  was changed at different FPT 
inhibitor II concentrations.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
62
■  FTI = 0 mM 4 .5 - ,  
♦  FTI = 500nM
4 -
▲ FTI = 5000nM
0.5 -
-10 -5 0 5 10 15 20
1/[FPP] (micromolar'1)
FIG. 24. Lineweaver-Burk double reciprocal plots of FTase inhibitor II. FTase- 
catalyzed reaction velocity (l/v) versus substrate concentrations (1/[S]) using 0 nM, 500 
nM, or 5,000 nM of FTase inhibitor II. A constant slope (Km/Vm) and various Km and 
Vm were found in three different concentrations of FTase inhibitor II.
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FIG. 25. Lineweaver-Burk double reciprocal plots of arglabin-DMA. FTase-catalyzed 
reaction velocity (1/v) versus substrate concentration (1/[S]) using various concentrations 
of arglabin-DMA (0 pM, 1 pM, 4 pM). The slopes (Km/Vm) of all three concentrations of 
arglabin-DMA were constant, but both Km and Vm changed with various concentrations 
of arglabin-DMA.
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The Effect of Arglabin-DMA on FTase Produced in Transformed Cells 
Farnesyltransferase Production in Arglabin-DMA Treated Ras/3T3 Cells
Equal numbers of Ras/3T3 cells were incubated with various concentrations of 
arglabin-DMA (0, 0.1, 1, 10, 50, and 100 |xM), or 0.25 pM of FTI-277 for 24 hours or 72 
hours, since the half-life of FTase in cells is around 24 hours. Cell lysates were generated, 
and the concentrations of cellular protein were determined by BCA protein assays. Equal 
amounts of cellular protein were separated in SDS-polyacrylamide gel, and the amounts 
of FTase in gels were determined by Western blot using rabbit anti-famesyltransferase 
monoclonal antibody. The densities of each band were quantitated using Quantity One 
densitometry software from Bio-Rad.
Two band sizes appear on Western blots: the top band (48.8 kDa) represents the FT 
P-subunit, and the bottom band (44.4 kDa) represents the FT a-subunit. Western blots for 
FTase after 24 hours and 72 hours of incubation with arglabin-DMA or FTI-277 are 
shown in figure 26A and figure 27A. There was no significant difference between 
densities of bands detected by densitometry (Fig. 26 B and Fig.27B). These results 
suggested that neither arglabin-DMA nor FTI-277 affected FTase production in Ras/3T3 
cells.
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FIG. 26. Western blot of FTase after 24-hour incubation with arglabin-DMA or FTI- 
277. Ras/3T3 cells were incubated with complete cell culture media containing 0, 0.1, 1, 
10, 50, or 100 pM of arglabin-DMA or 0.25 pM of FTI-277 for 24 hours. FTase in cellular 
protein was detected and shown in figure 26 A. The total densities of bands for each 
concentration group were shown in figure 26B. No significant difference was found 
between groups.
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FIG. 27. Western blot of FTase after 72-hour incubation with arglabin-DMA and FTI- 
277. Ras/3T3 cells were incubated with complete cell culture media containing 0, 0.1, 1, 
10, 50, or 100 pM of arglabin-DMA, or 0.25 pM of FTI-277 for 72 hours. FTase in 
cellular protein was detected and shown in figure 27A. The total densities of bands for 
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FTase Assay using FTase Produced in Ras/3T3 Cells
Equal numbers of Ras/3T3 cells were incubated with various concentrations of 
arglabin-DMA or FTI-277 for 2 hours, 1 day or 2 days. Cell lysates were generated, and 
the concentrations of cellular protein were determined by BCA protein assays. Equal 
amounts of cellular protein were used in the FTase assays. Tritiated 
famesylpyrophosphate and Ras protein were used as the substrates. Tritiated famesylated 
Ras protein was generated in proportion to the FTase activity of the cell lysate. Reactions 
using cell lysates generated from cells without arglabin-DMA treatment were used as the 
negative control. Reactions using cell lysates incubated with FTI-277 were the positive 
controls.
When low concentrations of arglabin-DMA (10, 50, 100, and 1,000 nM) were used 
on Ras/3T3 cells for a short period (2 hours), a significant reduction in the specific 
activity of FTase was found at thelO nM concentration of arglabin (p < 0.05) (Fig. 28). 
The reduction plateaued when the concentration o f arglabin-DMA reached 100 nM. The 
specific activity difference between 100 nM and 1,000 nM arglabin-DMA groups was not 
significant (p > 0.05). Percentage of FTase inhibition was calculated by comparing the 
specific activity with the no arglabin-DMA control. The highest inhibition of FTase 
activity was 59% when 100 nM arglabin-DMA was used on Ras/3T3 cells for 2 hours 
(Fig. 29). These results were derived from 3 separate experiments. The percentage of 
inhibition of FTase activity by 1,000 nM of FTI-277 was 90%. These results suggested 
that low concentrations (10-1,000 nM) of arglabin-DMA inhibited FTase activity after 2 
hours of incubation with Ras/3T3 cells. However, this inhibition was limited by the 
substrate availability in cells that may transform arglabin-DMA to a famesyltransferase
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inhibitor, such as phosphorylated arglabin-DMA.
When higher concentrations of arglabin-DMA (25, 50, 75, and 100 pM) were used 
on Ras/3T3 cells for longer times (1 day or 2 days), percentage inhibitions plateaued at 
75 pM for both incubation times (Fig. 30 and Fig. 31). After incubation with arglabin- 
DMA for these longer times, the enzyme activity of the newly synthesized FTase was 
inhibited by much higher concentrations of arglabin-DMA (50 pM to 100 pM). This may 
imply that arglabin-DMA was transformed to an FTase inhibitor inside of cells and this 
transformation was not reversible. Another possibility was that some arglabin-DMA or its 
derivatives were degenerated inside of cells after longer period o f incubation. Therefore, 
after large amount of newly synthesized FTase appeared in cells, more arglabin-DMA 
was needed to inhibit FTase activity.
THE EFFECT OF ARGLABIN-DMA ON RAS PROTEIN IN TRANSFORMED 
CELLS
The Effect of Arglabin-DMA on H-Ras Protein in Transformed Cells
Equal numbers of Ras/3T3 cells were incubated with various concentrations of 
arglabin-DMA (0.1, 1, 10, 50, and 100 pM) or 0.25 pM of FTI-277 (control) for 24 hours 
or 72 hours. Cell lysates were generated, and the concentrations of cellular protein were 
determined by BCA protein assays. Equal amounts of cellular protein were separated in 
SDS-polyacrylamide gel, transferred to PVDF membrane, and the amounts of H-Ras 
protein determined by western blot using rat anti-v-H-Ras monoclonal antibody. The 
recombinant H-Ras protein (Sigma, R-9894) was used as a positive control for the
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FIG. 28. Specific activity of FTase after 2-hour incubation with arglabin-DMA. A 
significant reduction in specific activity of FTase was found at 10 nM concentration of 
arglabin (p < 0.05). The reduction plateaued when the concentration of arglabin reached 
100 nM. The specific activity difference between 100 nM and 1,000 nM arglabin-DMA 
groups was not significant (p > 0.05).
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FIG. 29. Percentage of FTase inhibition after 2-hour incubation with arglabin-DMA. 
Percentage of FTase inhibition was calculated by comparing the specific activity with the 
no arglabin-DMA control. The highest inhibition of FTase activity was 59% when 100 
nM arglabin-DMA was used to incubate Ras/3T3 cells for 2 hours.
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FIG. 30. Percentage of FTase inhibition after 1-day incubation with arglabin-DMA. 
Percentage of inhibitions plateaued after 1-day incubation with 75 pM of arglabin-DMA.
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FIG. 31. Percentage of FTase inhibition after 2-day incubation with arglabin-DMA. 
Percentage of inhibitions plateaued after 2-day incubation with 75 pM of arglabin-DMA.
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western blot. The densities of each band were quantitated using Quantity One 
densitometry software from Bio-Rad.
The prenylated (processed) and non-prenylated (non-processed) Ras proteins were 
separated by electrophoresis and detected by Western blot (53, 58). The faster-migrating 
immunoreactive bands represented mature, fully processed protein, whereas the slower- 
migrating form was unprocessed protein (62) (Fig. 32, 33).). The relative molecular 
weight of the processed protein estimated from the Precision protein standard (BioRad, 
161-0373) was 21 + 1 kD. The Western blots for cells incubated with arglabin-DMA (0, 
0.1, 1, 10, 50, 100 pM) or FTI-277 (0.25 pM) for 24 hours or 72 hours are shown in 
Figures 32 A and 3 3 A, respectively. A trend of increasing densities of the slower- 
migrating bands was found as the concentration of arglabin-DMA increased from 0 pM 
to 100 pM, and the density of the slower-migrating band for the FTI-277 group reached 
the highest level (Fig. 32A and Fig. 33A). The ratio of densities of faster-migrating bands 
(processed H-Ras protein) to densities of slower-migrating bands (unprocessed H-Ras 
protein) was calculated and shown in Figures 32B and 33B. The percentage reduction of 
the ratio was calculated by comparing the ratio of densities to the no arglabin-DMA 
treatment control. After cells were incubated with 100 pM of arglabin-DMA for 24 hours 
or 72 hours, percentages of reduction of ratio of processed to unprocessed H-Ras protein 
were 18.6% and 9.5%, respectively (Fig. 32B and Fig. 33B). When cells were incubated 
with FTI-277 for 24 hours or 72 hours, the percentages of ratio reduction were 46% and 
26.5%, respectively. These results were derived from 4 separate experiments.
Equal amounts of cellular protein from various treatment groups were utilized in 
small GTPase-pull down assays. The complexes of GST-Rafl-RBD and active Ras
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protein were selectively eluted from glutathione discs, separated in SDS-polyacrylamide 
gel, transferred to PVDF membrane, and the amounts of H-Ras protein were determined 
by western blot using rat anti-v-H-Ras monoclonal antibody. There were multiple bands 
detected in the western blots (Fig. 34A-B). When cell lysates incubated with arglabin- 
DMA or FTI-277 for 24 hours were used for the pull-down assay, the bands with the 
highest density were found at relative molecular weight of 40 + 2 kD compared to the 
protein standard (Fig. 34A). No band with molecular weight of 21 + 1 kD was detected. 
This may be due to the Ras protein dimer formation during the pull-down process. The 
densities of bands were reduced significantly on lanes of 50 pM and 100 pM arglabin- 
DMA (Fig. 34A). When cell lysates incubated with arglabin-DMA or FTI-277 for 72 
hours were used for the pull-down assay, bands with relative molecular weight of 39 + 1 
kD were detected in all tested samples (Fig. 34B). Significant density reductions were 
found in lanes of 1 pM, 10 pM, 50 pM, and 100 pM arglabin-DMA and FTI-277. These 
data suggested that arglabin-DMA or FTI-277 inhibited active H-Ras formation in 
Ras/3T3 cells.
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FIG. 32. Western Blot of H-Ras after 24-hour incubation with Arglabin-DMA or FTI- 
277. A trend of increasing densities of slower-migrating bands was found as the 
concentrations of arglabin-DMA increased from 0 |iM to 100 gM, and the density of the 
slower-migrating band for FTI-277 group reached its highest level (Fig. 32A). The ratios 
of densities of faster-migrating bands (processed H-Ras protein) to densities of slower- 
migrating bands (unprocessed H-Ras protein) were calculated and shown in figure 32B.
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FIG. 33. Western Blot of H-Ras after 72-hour incubation with Arglabin-DMA or FTI- 
277. A trend of increasing on densities of slower-migrating bands was found as the 
concentrations of arglabin-DMA increased from 0 pM to 100 gM, and the density of the 
slower-migrating band for FTI-277 group reached the highest (Fig. 33A). The ratios of 
densities of faster-migrating bands (processed H-Ras protein) to densities of slower- 
migrating bands (unprocessed H-Ras protein) were calculated and shown in figure 33B.
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FIG. 34. Western blot of H-Ras protein after small GTPase pull-down assays. When 
cell lysates incubated with arglabin-DMA or FTI-277 for 24 hours were used for the pull­
down assay, the bands with the highest density were found at relative molecular weight 
of 40 + 2 kD compared to the protein standard (Fig. 34 A). The densities of bands reduced 
significantly after 50 pM and 100 pM arglabin-DMA incubation. When cell lysates 
incubated with arglabin-DMA or FTI-277 for 72 hours were used for the pull-down 
assay, bands with relative molecular weight of 39 + 1 kD were detected in all tested 
samples (Fig. 34B). Significant density reductions were found in lanes of 1 pM, 10 pM, 
50 pM, and 100 pM arglabin-DMA and FTI-277.
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The Effect of Arglabin-DMA on K-Ras Protein in Transformed Cells
Equal numbers of Ras/3T3 cells were incubated with various concentrations of 
arglabin-DMA (0.1, 1, 10, 50, and 100 pM) or 0.25 pM of FTI-277 (positive control) for 
24 hours. Cell lysates were generated, and the concentrations of cellular protein were 
determined by BCA protein assays. Equal amounts of cellular protein were separated in 
SDS-polyacrylamide gel, transferred to PVDF membrane, and the amounts of K-Ras 
protein were determined by Western blot using mouse anti-K-Ras monoclonal antibody. 
Cell lysates from rat K-Ras transformed kidney (KNRK) cells (Santa Cruz, Inc. SC- 
2214), was used as a positive control for Western blot. The densities of each band in 
tested samples were quantitated using Quantity One densitometry software from Bio- 
Rad.
The KNRK cell lysate control showed two bands, one faster-migrating band 
(processed K-Ras protein) and one slower-migrating band (unprocessed K-Ras protein) 
(Fig. 35A). The relative molecular weight of the processed protein estimated from the 
Precision protein standard (BioRad, 161-0373) was 21 + 1 kD. Only one band in each 
sample was detected in Western blot for Ras/3T3 cell lysates that was incubated with 
arglabin-DMA, FTI-277, or no treatment control (Fig. 35A). All tested samples have only 
the faster-migrating bands (processed K-Ras protein) when compared to the KNRK cell 
lysate control. The densities of each test samples are shown in figure 35B. No significant 
difference was found between band densities of all test samples. The data was collected 
from two separate experiments. These results suggested that FTase inhibitors have no 
effect on K-Ras prenylation, since all K-Ras were post-translational modified by 
geranylgeranylation of GGTasel.
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FIG. 35. Western blot of K-Ras after 24-hour incubation with arglabin-DMA or FTI- 
277. All tested samples only have the faster-migrating bands (processed K-Ras protein) 
when compared to the KNRK cell lysate control (Fig. 35A). No significant differences 
were found between band densities of all test samples (Fig. 35B).
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THE EFFECT OF ARGLABIN-DMA ON RHO PROTEIN IN TRANSFORMED 
CELLS
The Effect of Arglabin-DMA on RhoA Protein in Transformed Cells
Equal numbers of Ras/3T3 cells were incubated with various concentrations of 
arglabin-DMA (0.1, 1, 10, 50, and 100 gM) or 0.25 gM of FTI-277 (positive control) for 
24 hours and 72 hours. Cell lysates were generated, and the concentrations of cellular 
proteins were determined by BCA protein assays. Equal amounts of cellular protein were 
separated in SDS-polyacrylamide gel, transferred to PVDF membrane, and the amount of 
RhoA protein were determined by western blot using mouse anti-RhoA monoclonal 
antibody. The Hela cell lysate (Santa Cruz, Inc. SC-2200) from human epithelioid 
carcinoma cells was used as a positive control for western blot. The densities of each 
band of all tested samples were quantitated using Quantity One densitometry software 
from Bio-Rad.
Two bands were detected from Hela cell lysate control: the faster migrating band 
(processed RhoA protein) and the slower migrating band (unprocessed RhoA protein) 
(Fig. 36A-B and Fig. 37A). The relative molecular weight of the processed protein 
estimated from the Precision protein standard (BioRad, 161-0373) was 21 + 1 kD. After 
24 horns of incubation with various concentrations of arglabin-DMA or FTI-277, one 
band from each sample was detected in Western blots (FIG. 36A-B). The bands from 10 
gM, 50 gM, lOOgM arglabin-DMA, and FTI-277 were the slower migrating bands when 
compared to the Hela cell lysate control. The densities of bands from lanes of control (0 
gM) and 0.1 gM arglabin-DMA were higher than the rest of the bands and moved faster 
than the rest of the samples. These faster migrating bands may be caused by an uneven
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distribution of electrical voltage of the gel, or caused by processed RhoA protein (faster- 
migrating RhoA protein) in control and 0.1 pM arglabin-DMA treated sample. The 
densitometry data is shown in figure 36C. The bands from control samples showed the 
highest densities. The error bars showed the range from two separate experiments.
After 72 hours incubation with various concentrations of arglabin-DMA or FTI-277, 
still only one band was detected in all tested samples (Fig. 37A-B). The migration pattern 
of bands was similar to the 24-hour incubation samples. The bands from 10 pM, 50 pM, 
100 pM arglabin-DMA and FTI-277 controls were slower-migrating bands when 
compared to the Hela cell lysate control (Fig. 37A-B). The bands from control (0 pM) 
and 0.1 pM arglabin-DMA were faster-migrating compared to the Hela cell lysate 
control. The densities of bands from two separate experiments were summarized in figure 
37C. After 72 hours of incubation, there was no significant density difference between 
bands of all samples.
Equal amounts of cellular protein from various treatment groups were utilized in 
small GTPase-pull down assays. The complexes of GST-Rhotekin-RBD and active RhoA 
protein were selectively eluted from glutathione discs, separated in SDS-polyacrylamide 
gel, transferred to a PVDF membrane, and the amounts of RhoA protein determined by 
western blot using mouse anti-RhoA monoclonal antibody. When cell lysates incubated 
with arglabin-DMA or FTI-277 for 72 hours were used for the pull-down assay, two 
bands with the highest densities were found at relative molecular weight of 40 + 2 kD and 
36 + 1 kD, respectively (Fig. 38). The 36 + 1 kD bands were detected in all tested 
samples, while the 40 + 2 kD bands were detected in lanes for the control and 0.1 pM, 1 
pM, 10 pM and 50 pM arglabin-DMA. The fusion protein of GST-Rhotekin has the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
82
molecular weight of 36 kD, according to the manufacturer’s guide. The protein with 
molecular weight of 40 ± 2 kD could be the dimer of active RhoA protein. This protein 
was not found in 100 pM arglabin-DMA and 0.25 pM of FTI-277. These results 
indicated that arglabin-DMA and FTI-277 may have inhibited active RhoA formation in 
Ras/3T3 cells.
The Effect of Arglabin-DMA on RhoB Protein in Transformed Cells
Equal numbers of Ras/3T3 cells were incubated with various concentrations of 
arglabin-DMA (0.1, 1, 10, 50, and 100 pM) or 0.25 pM of FTI-277 (control) for 24 
hours. Cell lysates were generated and the concentrations of cellular protein were 
determined by BCA protein assays. Equal amounts of cellular protein were used for 
immunoprecipitation with Rabbit anti-RhoB IgG. The eluted material from protein G- 
agarose beads containing antigen-antibody complex were separated in SDS- 
polyacrylamide gel, transferred to PVDF membrane, and the amounts of RhoB protein 
were determined by Western blot using mouse anti-RhoB monoclonal antibody. The 
densities of each band of all tested samples were quantitated using Quantity One 
densitometry software from Bio-Rad.
After 24-hour incubation with various concentrations of arglabin-DMA or FTI-277, 
two bands from each sample were detected in western blot (Fig. 39A). The band with 
significantly higher density was the faster-migrating band (processed RhoB) and the band 
with lower density was the slower-migrating band (unprocessed RhoB) (Fig. 39A). The 
relative molecular weight of the processed protein estimated from the Precision protein 
standard was 21 + 1 kD. The densities of the fast migrating bands quantitated by 
densitomety showed no significant difference between all samples (Fig. 39B).
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FIG. 36. Western blot of RhoA after 24-hour incubation with arglabin-DMA or FTI- 
277. The bands from 10 pM, 50 pM, lOOpM arglabin-DMA, and FTI-277 were the slower 
migrating bands when compared to the Hela cell lysate control (Fig. 36A-B). The densities 
of bands from control (0 pM) and 0.1 pM arglabin-DMA were higher than the rest of 
bands and moving faster than the rest of samples. The bands from control samples showed 
the highest densities (Fig. 36C).
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FIG. 37. Western blot of RhoA after 72-hour incubation with Arglabin-DMA or FTI- 
277. The bands from 10 gM, 50 gM, 100 gM arglabin-DMA and FTI-277 controls were 
slower-migrating bands when compared to the Hela cell lysate control (Fig. 37A-B). 
After 72 hours of incubation, there was no significant density difference between bands 
of all samples (Fig. 37C).
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FIG. 38. Western blot of RhoA protein after GTPase pull-down assay. When cell 
lysates incubated with arglabin-DMA or FTI-277 for 72 hours were used for the pull­
down assay, two bands with the highest densities were found at relative molecular 
weights of 40 + 2 kD and 36+1  kD, respectively. The 36 + 1 kD bands were detected in 
all tested samples, while the 40 + 2 kD bands were detected in lanes for control and 0.1 
pM, 1 pM, 10 pM and 50 pM arglabin-DMA.
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FIG. 39. Western blot of RhoB after 24-hour incubation with arglabin-DMA or FTI- 
277. The bands with significantly higher density were the faster-migrating bands 
(processed RhoB protein) and the bands with lower density were the slower-migrating 
bands (unprocessed RhoB protein) (Fig. 39A). The densities of bands quantitated by 
densitomety showed no significant difference between all samples (Fig. 39B).
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THE EFFECTS OF ARGLABIN-DMA ON P21/WAF1/CIP1 PROTEIN IN 
TRANFORMED CELLS
Equal numbers of Ras/3T3 cells were incubated with various concentrations of 
arglabin-DMA (0.1, 1, 10, 50, and 100 |ilM) or 0.25 pM of FTI-277 (control) for 24 hours 
and 72 hours. Cell lysates were generated, and the concentrations of cellular protein were 
determined by BCA protein assays. Equal amounts of cellular protein were used for 
immunoprecipitation using rabbit anti-p21 IgG. The protein G-agarose beads containing 
antigen-antibody complex were separated in SDS-polyacrylamide gel, transferred to 
PVDF membrane, and the amount of p21/WAFl/CIPl protein were determined by 
Western blot using mouse anti-p21/WAFl monoclonal antibody. Direct Western blots 
without immunoprecipitation were also performed using equal amounts of cellular 
protein. The full-length p21/WAFl/CIPl (SC-4078) from mouse origin produced in E. 
coli was used as a positive control for Western blot. The densities of each band of all 
tested samples were quantitated using Quantity One densitometry software from Bio- 
Rad.
After 24 hours incubation with various concentrations of arglabin-DMA or FTI-277, 
one major band around 20 kD was detected in all samples (Fig. 40A-C). No significant 
density difference was found between samples incubated with various concentrations of 
arglabin-DMA (p > 0.05) (Fig. 40D). These data were derived from three separate 
experiments. Decreased overall density in the FTI-277 control was found in two of three 
experiments.
After 72 hours of incubation, a trend of increasing density was found from the no 
treatment control group to the 100 pM of arglabin-DMA treatment group (Fig. 41A-C).
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Density increased compared to the no treatment control (23 + 5% and 36 + 9% for 50 pM 
and 100 pM of arglabin-DMA treatment groups, respectively) (Fig. 41D). These were the 
results from three separate experiments. Decreased densities in the FTI-277 control were 
found in all three experiments. This data suggested that arglabin-DMA and FTI-277 
affected Ras/3T3 cell cycle by different mechanisms.
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FIG. 40: Western blot of p21AVAFl/CIPl after 24-hour incubation with arglabin- 
DMA or FTI-277. No significant density difference was found between samples 
incubated with various concentration of arglabin-DMA (p > 0.05) (Fig. 40A-D). These 
data were derived from three separate experiments. Decreased density in lane of FTI-277 
control was found in two of the three experiments.
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FIG. 41. Western blot of p21/WAFl/CIPl after 72-hour incubation with arglabin- 
DMA or FTI-277. A trend of increasing density was found from no treatment control 
group to 100 pM of arglabin-DMA treatment group (Fig. 41A-D). Decreased densities in 
lanes of FTI-277 control were found in all three experiments.
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DISCUSSION
The most frequently detected alterations in oncogenes in human cancers are 
mutations in the ras family of oncogenes (49). The first and most critical post- 
translational modification of the Ras protein is famesylation catalyzed by 
famesyltransferase (20). Consequently, inhibitors of famesyltransferase have been 
proposed as potential agents for treating cancers. Three major groups of 
famesyltransferase inhibitors have been developed (20): CAAX pepiddomimetics (such 
as FTI-277), heterocyclic FTIs (such as SCH66336), and FPP competitive compounds 
(such as FPT inhibitor II). Arglabin-dimethylaminohydrochloride (arglabin-DMA) is 
used in current anti-tumor treatments in the Republic of Kazakstan (1, 2, 51). 
Shaikenov’s studies showed that arglabin-DMA inhibited the incorporation of 
famesylpyrophosphate into H-Ras protein by FTase with an IC50 of 25 pM (51, 52). 
Their studies have shown promise in suppressing the growth of various tumor cells by 
arglabin-DMA (51, 52). However, the mechanism of arglabin-DMA cytotoxicity and 
cytostatic effects on tumor cells at the molecular and cellular level is still unclear. The 
current study was undertaken to determine the famesyltransferase inhibitory activity of 
arglabin-DMA and to investigate the effects of arglabin-DMA on Ras protein, Rho 
protein and cyclin kinase inhibitor p21/WAFl/CIPl.
Based on Shaikenov’s studies, arglabin-DMA inhibits the anchorage-dependent 
proliferation and anchorage-independent growth of neuroblastoma cells at the similar 
concentrations (IC50 = 10 pg/mL or 30.5 pM), and inhibits H-Ras transformed cells 
(Ras/3T3 cells) at concentration of 2 pg/mL (6.1 pM) (IC50) in the soft-agar colony
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formation assay (52). The present study used a MTT based in vitro toxicology assay kit to 
measure metabolic activity of Ras/3T3 cells that were incubated with various 
concentrations of arglabin-DMA. The data revealed that the 50% inhibition concentration 
of arglabin-DMA for Ras/3T3 cells was 10.34 pM, which is close to the IC50 in the soft- 
agar colony formation assay.
Studies of the effect of arglabin-DMA on famesyltransferase showed different results 
when using expressed FTase and Ras/3T3 cell lysates. When the FTase assay was 
performed using expressed atnd purified FTase, the IC50 for Arglabin-DMA was 2.9 mM, 
which was 24,000 times higher than FPT inhibitor II (119 nM). Lineweaver-Burk double 
reciprocal plots indicated competitive inhibition of FTase by FPT inhibitor II, and 
uncompetitive inhibition of FTase by FTase Inhibitor II and arglabin-DMA. When the 
FTase assay was performed using Ras/3T3 cell lysates as a source of FTase, the highest 
percentage of arglabin-DMA inhibition was 50-60% compared to the no arglabin-DMA 
treatment control, and this inhibition plateaued when the arglabin-DMA concentration 
reached 100 nM or higher. These results suggest that arglabin-DMA was transformed in 
cells and this transformation was limited by the substrate availability in cells. Data 
generated in Shaikenov’s laboratory suggested that arglabin-DMA is transformed by 
phosphorylation within cells and that the phosphorylated derivative of arglabin-DMA can 
prevent famesylation of Ras proteins (51). The molecular modeling results from the 
present study also indicated that the phosphorylated arglabin-DMA has significantly 
higher binding affinity than arglain-DMA alone. Unprocessed arglabin-DMA alone was 
not a potent FTase inhibitor. However, a derivative of arglabin-DMA in Ras/3T3 cells 
showed inhibitory activity to FTase at nanomolar or higher concentrations, and this
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inhibitory capability was limited by the availability of other substrates that can be used to 
transform arglabin-DMA within cells. ATP is a possible substrate based on Dr. 
Saikenov’s study.
The Rho GTPases are essential for Ras-induced oncogenic transformation (35) and 
activated Rho acts synergistically with activated Raf in cell transformation. Raf, with 
activated serine/threonine kinase activity, sends positive signals down a kinase cascade 
(the mitogen-activated protein kinase pathway) and prompts cells to move through the G1 
phase of the cell cycle towards S phase (42, 44, 50). Excessive signaling from Ras/Raf 
induces p21/WAFl/CIPl, which blocks entry into S phase. RhoA overcomes the cell- 
cycle block by suppressing expression of p21/WAFl/CIPl (42, 44, 50) (Fig. 3). Although 
some evidence showed the involvement of RhoB in the anti-tumor activity of FTIs 
(11,17), direct evidence implicating RhoB in the mechanism of action of FTIs in human 
tumors is lacking.
FTIs were originally developed as a Ras-targeted therapy, because Ras protein plays 
a crucial role in cellular signal transduction pathways, and the first and most critical post- 
translational modification of Ras is famesylation catalyzed by the FTase (20, 40). Four 
isoforms of Ras proteins have been discovered (63). Ki-Ras4A, Ki-Ras4B, and N-Ras 
proteins can be either famesylated or geranylgeranylated, whereas H-Ras proteins are 
singly famesylated (48, 63). Expressions of H-Ras and K-Ras (including both Ki-Ras4A 
and Ki-Ras4B) in Ras/3T3 cells that were incubated with various concentrations of 
arglabin-DMA (0.1, 1, 10, 50, and 100 pM) or 0.25 pM of FTI-277 (control) were 
examined in this study. Western blots and densitometry showed significant decreases in 
the ratio of processed to unprocessed H-Ras protein in cell lysates incubated with 100 pM
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of arglabin-DMA and cell lysates incubated with FTI-277 for 24 hours and 72 hours. 
Western blots of active H-Ras protein from small GTPase pull-down assays showed 
significant reduction of active H-Ras production after incubation with 50 pM of arglabin- 
DMA for 24 hours, or 1 pM of arglabin-DMA for 72 hours. The K-Ras can undergo 
geranylgeranylation catalyzed by GGT-I when cells are treated with FTIs (63). Thus, 
tumors bearing the mutant Ki-ras4B isoform should be resistant to FTIs; however, some 
tumors bearing Ki-ras4B mutations are clearly responsive to FTI treatments. In the 
present study, only processed K-Ras protein was detected and no significant density 
differences between bands of all samples were found after 24 hours of incubation with 
arglabin-DMA. This result indicated that processing of K-Ras protein was not affected by 
arglabin-DMA or FTI-277. Famesylation of H-Ras was affected by arglabin-DMA; 
however, this inhibition cannot account for the cytotoxicity of arglabin-DMA alone, since 
H-Ras is one of the four Ras proteins in Ras/3T3 cells and H-Ras is only involved in part 
of Ras signaling pathway. K-Ras was not affected by arglabin-DMA or FTI-277.
Dr. Prendergast and his research team at the Wistar Institute suggested that cell 
growth inhibition by famesyltransferase inhibitors is mediated by gain of 
geranylgeranylated RhoB (17, 32). Dr. Chen‘s results (11) supported the conclusion that 
alteration of RhoB prenylation is both necessary and sufficient to the FTI mechanism in 
malignant cells. Both RhoB-F and RhoB-GG induce apoptosis, inhibit oncogenic 
signaling, and suppress transformation in vitro and in vivo (11). RhoB proteins can be 
either famesylated or geranylgeranylated, whereas RhoA proteins are singly 
geranylgeranylated (48, 63). The half-life of RhoB protein is about 2 hours and that of 
RhoA protein is around 30 hours. The results of the present study showed that only
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
95
unprocessed RhoA was detected by Western blot after 24 hours or 72 hours of incubation 
with 10 pM, 50 pM, lOOpM arglabin-DMA, and FTI-277. There were no significant 
density differences between bands of all samples. Western blots of active RhoA protein 
from small GTPase pull-down assays showed significant reduction of active RhoA 
production after 72 hours of incubation with 50 pM of arglabin-DMA. These results 
suggested that production of processed or activated RhoA protein was affected by 
arglabin-DMA and FTI-277. In the present study, only processed RhoB protein was 
detected and no significant density difference between bands of all samples was found 
after 24 hours of incubation with arglabin-DMA. This result indicated that processing of 
RhoB protein was not affected by arglabin-DMA or FTI-277.
The 21 kD protein of the WAF1 gene is found in a complex involving cyclins,
CDKs, and proliferating cell nuclear antigen (PCNA) in normal cells but not in 
transformed cells and appears to be a universal inhibitor of CDK activity (24). One 
consequence of p21/WAFl/CIPl binding to and inhibiting CDKs is the prevention of 
CDK-dependent phosphorylaition and subsequent inactivation of the retinoblastoma (Rb) 
protein that is essential for cell cycle progression (24). P21/WAF1/CIP1 is, therefore, a 
potent and reversible inhibitor of cell cycle progression at both the G1 and G2 check 
points, presumably to allow sufficient time for DNA repair to be completed (19). Study 
of the effects of arglabin-DMA on cyclin kinase inhibitor p21/WAFl/CIPl protein was 
performed using the Ras/3T3 cell line. Equal amounts of protein lysates from Ras/3T3 
cells that were incubated with various concentrations of arglabin-DMA (0.1, 1, 10, 50, 
and 100 |iiM) or 0.25 pM of FTI-277 (control) for 24 hours or 72 hours were used to 
detect p21/WAFl/CIPl proteins. This study showed a trend of increasing
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p21/WAFl/CIPl production after 72 hours of incubation with arglabin-DMA and this 
trend was not found in the FTI-277 control, which suggested a different cellular 
mechanism of cytotoxic effect for arglabin-DMA and FTI-277. However, this study only 
detected p21/WAFl/CIPl protein in the whole cell lysates, which include the 
p21/WAFl/CIPl protein in a complex involving cyclins, CDKs, and proliferating cell 
nuclear antigen (PCNA) and p21/WAFl/CIPl protein free in cytoplasm.
In summary, cellular mechanism of arglabin-DMA cytotoxic effect was investigated 
in the present study. First, arglabin-DMA itself is not a potent FTase inhibitor, however, 
arglabin-DMA was transformed to a derivative in Ras/3T3 cells that can inhibit FTase 
activity at nanomolar or higher concentrations, and this inhibitory capability was limited 
by the availability of other substrates that can be used to transform arglabin-DMA within 
cells. Secondly, H-Ras famesylation, RhoA geranylgeranylation, andp21/WAFl/CIPl 
production were affected by arglabin-DMA, while K-Ras prenylation and RhoB 
prenylation were not influenced by arglabin-DMA treatments (Fig. 42).
Since geranylgeranylations of RhoB and K-Ras were not affected by arglabin-DMA 
and famesylations of RhoB and K-Ras were inhibited by arglabin-DMA, the balances 
between RhoB-F and RhoB-GG or K-Ras-F and K-Ras-GG were disturbed. The half-life 
of RhoB is 2 hours and the half-life of K-Ras protein is around 24 hours. This means that 
large amounts of geranylgeranyltransferase (GGT) and geranylgeranylpyrophosphate 
(GGPP) were used for RhoB and K-Ras prenylation. The half-life of RhoA is around 30 
hours, RhoA can only be geranylgeranylated and the availabilities of GGT and GGPP for 
geranylgeranylation of RhoA were affected by arglabin-DMA treatments. When H-Ras 
protein prenylation was inhibited by arglabin-DMA, K-Ras protein prenylation was not
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affected by arglabin-DMA, the overall signals from Ras to Raf may be reduced, but most 
of signals still existed, which can induce p21/WAFl/CIPl expression. RhoA should 
overcome the cell-cycle block by suppressing expression of p21/WAFl/CIPl in normal 
circumstances (42, 44, 50), but RhoA geranylgeranylation was inhibited due to lack of 
GGT and GGPP after arglabin-DMA treatments. Thus, the increased expressions of 
p21/WAFl/CIPl were found after 72 hours treatment of arglabin-DMA. However, this 
increasing p21/WAFl/CIPl was not found in FTI-277 treated group, which suggests that 
the cellular mechanism of arglabin-DMA cytotoxic effect is different from the cellular 
mechanism of FTI-277.
Taken together, arglabin-DMA can be transformed to a derivative in Ras/3T3 cells 
that will inhibit FTase activity at nanomolar or higher concentrations. The inhibition of 
Ras and RhoB protein famesylation will shift more active K-Ras and RhoB proteins to 
geranylgeranylated forms after 24 to 72 hours incubation. The availability of GGT and 
GGPP for RhoA geranylgeranylation will be reduced, which can decrease the inhibitory 
effect of RhoA onp21/WAFl/CIPl production. Increasing p21/WAFl/CIPl production 
can block Ras/3T3 cells at G1 phase of cell cycle, thus inhibits DNA synthesis and cell 
proliferation. Understanding of the cellular mechanism of arglabin-DMA cytotoxic 
effects should help clinicians to determine the dose of arglabin-DMA for treatment and to 
use arglabin-DMA in combination with metabolical substrate (such as ATP) in cancer 
treatments. Detection of p21/WAFl/CIPl in tumor cells may be used as a marker of 
effectiveness of arglabin-DMA treatments.
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FIG. 42. Diagram of active Ras, Rho, and p21/WAFl/CIPl protein production affected 
by arglabin-DMA in Ras/3T3 cells.
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SUMMARY
Arglabin-DMA itself is not a potent FTase inhibitor, however, arglabin-DMA was 
transformed to a derivative in Ras/3T3 cells that can inhibit FTase activity at nanomolar 
or higher concentrations, and this inhibitory capability was limited by the availability of 
other substrates that can be used to transform arglabin-DMA within cells. H-Ras 
famesylation, RhoA geranylgeranylation, and cyclin kinase inhibitor p21 /WAF1/CIP1 
production were affected by arglabin-DMA, while K-Ras prenylation and RhoB 
prenylation were not influenced by arglabin-DMA treatments.
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APPENDIX A












Frame 1 -61.99 -64.62 -92.71 -82.06 -86.93 -63.61 -45.96
Frame2 -55.26 -64.63 -98.13 -65.36 -79.58 -48.93 -45.45
Frame3 -63.97 -56.78 -91.37 -77.49 -78.42 -58.62 -45.04
Frame4 -72.41 -64.95 -85.42 -68.86 -82.41 -54.61 -39.65
Frame5 -57.63 -64.87 -82.74 -75.04 -81.04 -46.71 -53.86
Frame6 -51.59 -59.53 -85.56 -49.38 -70.68 -65.91 -49.19
Frame7 -62.03 -71.19 -56.14 -60.72 -84.64 -56.76 -54.61
Frame8 -61.45 -57.87 -73.81 -60.33 -71.13 -69.94 -46.93
Frame9 -59.42 -62.25 -71.84 -65.53 -79.31 -53.24 -42.48
FrametO -62.42 -70.14 -84.15 -54.57 -74.91 -57.43 -46.51
Mean -60.817 -63.68 -82.19 -65.93 -78.91 -57.57 -46.97
APPENDIX B
TABLE 4. Statistical evaluation of the binding affinity between FTase and various 
ligands. ANOVA single factor. Probability level: 0.05
Groups Count Sum Average Variance
FPP 10 -608.17 -60.817 30.92033444
Phosphorylated Arglabin-DMA 10 -636.83 -63.683 22.62002333
FPT Inhibitor II 10 -821.86 -82.186 147.8554711
FTI-277 10 -659.34 -65.934 105.2587156
FPT Inhibitor III 10 -789.03 -78.903 28.78446778
FTase Inhibitor 11 10 -575.73 -57.573 53.41153444
Arglabin-DMA 10 -469.68 -46.968 21.30901778
ANOVA
Source of Variation SS df MS F P-value F crit
Between Groups 8889.07964 6 1481.51327 25.28428888 4.693E-15 2.246409281
Within Groups 3691.43608 63 58.5942235
Total 12580.51572 69
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